Textbook Litts Drug Eruption Reaction Manual 24E Jerome Z Litt Ebook All Chapter PDF

Litt's Drug Eruption & Reaction Manual
24E Jerome Z. Litt

Visit to download the full and correct content document:
https://textbookfull.com/product/litts-drug-eruption-reaction-manual-24e-jerome-z-litt/
More products digital (pdf, epub, mobi) instant
download maybe you interests ...
Litt's drug eruption & reaction manual Shear
https://textbookfull.com/product/litts-drug-eruption-reaction-
manual-shear/
Cooking as a Chemical Reaction: Culinary Science with

Experiments Z. Sibel Özilgen
https://textbookfull.com/product/cooking-as-a-chemical-reaction-
culinary-science-with-experiments-z-sibel-ozilgen/
Spring Cookbook 1st Edition Jaglale Jerome
https://textbookfull.com/product/spring-cookbook-1st-edition-
jaglale-jerome/
Reaction Engineering 1st Edition Shaofen Li
https://textbookfull.com/product/reaction-engineering-1st-
edition-shaofen-li/
Introduction to optical microscopy 2nd Edition Jerome
Mertz
https://textbookfull.com/product/introduction-to-optical-
microscopy-2nd-edition-jerome-mertz/
Mathematics for Enzyme Reaction Kinetics and Reactor

Performance, 2 Volume Set (Enzyme Reaction Engineering)
1st Edition F. Xavier Malcata
https://textbookfull.com/product/mathematics-for-enzyme-reaction-
kinetics-and-reactor-performance-2-volume-set-enzyme-reaction-
engineering-1st-edition-f-xavier-malcata/
Fundamentals of Structural Engineering 2nd Edition

Jerome J. Connor
https://textbookfull.com/product/fundamentals-of-structural-
engineering-2nd-edition-jerome-j-connor/
Atmospheric Reaction Chemistry 1st Edition Hajime

Akimoto (Auth.)
https://textbookfull.com/product/atmospheric-reaction-
chemistry-1st-edition-hajime-akimoto-auth/
Foundations of Chemical Reaction Network Theory Martin

Feinberg
https://textbookfull.com/product/foundations-of-chemical-
reaction-network-theory-martin-feinberg/
24th
EDITION
Jerome Z. Litt
Neil H. Shear
Boca Raton London New York
CRC Press is an imprint of the

Taylor & Francis Group, an informa business
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2018 by Taylor & Francis Group, LLC

CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Printed on acid-free paper
International Standard Book Number-13: 978-0-8153-6699-7 (Pack – Paperback and eBook)

International Standard Book Number-13: 978-1-138-49097-0 (Hardback)
This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts
have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any
legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear
that any views or opinions expressed in this book by individual editors, authors or contributors are personal to
them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained
in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a sup-
plement to the medical or other professional’s own judgement, their knowledge of the patient’s medical history,
relevant manufacturer’s instructions and the appropriate best practice guidelines. Because of the rapid advances in
medical science, any information or advice on dosages, procedures or diagnoses should be independently verified.
The reader is strongly urged to consult the relevant national drug formulary and the drug companies’ and device
or material manufacturers’ printed instructions, and their websites, before administering or utilizing any of the
drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is
appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional
to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and
publishers have also attempted to trace the copyright holders of all material reproduced in this publication and
apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright mate-
rial has not been acknowledged please write and let us know so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or
utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including
photocopying, microfilming, and recording, or in any information storage or retrieval system, without written
permission from the publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.com
(http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Dan-
vers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a
variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of
payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for
identification and explanation without intent to infringe.
Visit the Taylor & Francis Web site at

http://www.taylorandfrancis.com
and the CRC Press Web site at

http://www.crcpress.com
CONTENTS
Introduction v
Drug profiles: generic names A–Z 1
Descriptions of important reactions 305
Drugs that cause important reactions 311
Main classes of drugs 345
Classes of drugs that can cause important interactions 351
Class reactions 353
ACE inhibitors 353
Antiarrhythmics 355
Antibiotics, macrolide 357
Anticonvulsants 358
Antidepressants, tricyclic 361
Antihistamines (H1) 362
Antimalarials 363
Antipsychotics 365
Benzodiazepines 367
Beta blockers 368
Biologics 369
Bisphosphonates 374
Calcium channel blockers 375
Cephalosporins 377
Disease-modifying antirheumatic drugs (DMARDS) 378
DPP-4 inhibitors 383
Epidermal growth factor receptor (EGFR) inhibitors 384
Fluoroquinolones 387
Non-steroidal anti-inflammatory drugs (NSAIDS) 389
Proton pump inhibitors (PPI) 392
Statins 394
TNF inhibitors 395
Tyrosine-kinase inhibitors 398
Concordance of synonyms and trade names with
generic names 403
iii
To Vel – my Muse
JZL
Editors’ introductory notes
Any drug has the potential to cause an adverse reaction. An adverse drug reaction (ADR) is an unwanted, unpleasant, noxious,
or harmful consequence associated with the use of a medication that has been administered in a standard dose by the proper
route, for the purpose of prophylaxis, diagnosis, or treatment. Death is the ultimate adverse drug event.
ADRs are a major problem in drug therapy. They are the most common of all iatrogenic illnesses that complicate up to 15%
of therapeutic drug courses, and are a leading cause of morbidity and mortality in healthcare. ADRs should therefore be con-
sidered in the differential diagnosis of a wide variety of medical disorders. Many more people – particularly the elderly – are
taking more and more prescription and over-the-counter medications. In addition, new drugs are appearing in the medical
marketplace on an almost daily basis. It is unsurprising, then, that more and more drug reactions and cutaneous eruptions are
emerging.
Prevention, diagnosis and treatment of adverse drug events are becoming increasingly complex, and it is to be expected that
physicians in all specialties are often perplexed by the nature of ADRs. To this end, I now offer a new and improved edition
that has evolved from the treasured Drug Eruption Reference Manual of previous editions. I hope that you will find this new
edition informative and valuable.
Enjoy!
Jerome Z. Litt, M.D.
“Is it safe?”
I am frequently asked that big question from a patient: "Is it safe?" This text is meant to help all prescribers, dispensers and
patients understand what the risk of harm might be; whether it is from a drug reaction or interaction, Litt's is the go-to infor-
mation source. How does this information help answer the unanswerable? Simply put, safety is a process, not a question. With
the right information at hand a safe environment can thrive; the most up-to-date relevant data help peel away background
noise from a seemingly infinite number of sources. This new edition adds additional support to a risk management environ-
ment, and we will continue to provide the most up-to-date and relevant information. I look forward to feedback and sugges-
tions. I thank Jerry Litt for this great opportunity and the awesome work of the team at T&F to keep on top of all new
medications that are making the landscape even more complex.
Neil H. Shear, M.D., F.R.C.P.C., F.A.C.P.
Litt’s Drug Eruption & Reaction Manual – at a glance

This 24th edition has been revised and updated throughout to present a quick clinical reference guide to adverse drug
reactions (ADRs), side effects, drug interactions and other safety information for prescription and over-the-counter medica-
tions. There is also material on reactions caused by classes of drugs, enabling you to see at a glance whether a reaction is
common to all the drugs in that particular class, or to a majority of them, or only to a significant few.
The aims of this edition remain:
1. To help medical practitioners make informed and safe decisions when diagnosing and prescribing, and also when
generally seeking information.
2. To help healthcare professionals remain pharmacovigilant.
3. To provide all physicians, lecturers, educators and pharmacists with an easy-to-use and reliable quick reference tool.
The full and comprehensive picture for all drugs – from which our information derives – can be found at our website database
(www.drugeruptiondata.com), which is updated continually. Space in the manual is, unfortunately, constrained, so full profiles
for various generic drugs have been eliminated from this print manual because either they have been withdrawn from the
marketplace or they are rarely, if ever, prescribed today; new to this edition are links to their basic profiles in the website
database. Important new drugs added to this edition of the manual are noted with an asterisk.
v
A note on ADRs
The incidence and severity of ADRs are influenced by a number of factors:
1. Patient-related factors:
• Age – geriatric, pediatric, adolescent . . . older patients are taking more medications—hence more of a possibility of
developing reactions; pediatric patients have more delicate skins; hormonal changes occur in adolescents . . . All these
factors play roles in the development of possible adverse reactions.
• Gender – male or female – and if the latter, then pregnant/breast-feeding/menopausal . . .
• Disease – not only the disease being treated, but also other pre-existing health conditions and comorbid diseases. For
example, atopic patients are at increased risk for serious allergic reactions. Also, there would be an increased risk for
hypersensitivity drug reactions if the patient has asthma or lupus erythematosus.
• Genetics – a patient could have abnormal drug metabolism by cytochrome P450 due to inheriting abnormal alleles.
• Geography – patients living in sunny climes could develop photoxicities from photosensitizing drugs more readily than
those who inhabit cooler, less sunny climates.
2. Drug-related factors:
• Type/class of drug – for example, there is a heightened risk of hypersensitivity with the use of beta-blockers (see further the
tables on class reactions).
• Duration of therapy – the longer a patient maintains the therapy, the greater the possibility that he/she could develop a
reaction.
• Dosage – the greater the dosage, the more likely an adverse side effect.
• Bioavailability – the extent to and rate at which the drug enters systemic circulation, thereby accessing the site of action.
• Interactions with other drugs – for example, synergistic QT prolongation can occur when two QT prolonging agents, such
as erythromycin + ritonavir, are used together.
• Route of administration – intramuscular, intravenous, subcutaneous, and topical administrations are more likely to cause
hypersensitivity reactions; oral medications are less likely to result in drug hypersensitivity.
The terms “drug allergy,” “drug hypersensitivity,” and “drug reaction” are often used interchangeably. Drug allergy specific-
ally refers to a reaction mediated by IgE; drug hypersensitivity is an immune-mediated response to a drug agent in a sensitized
patient; and drug reactions comprise all adverse events related to drug administration, regardless of etiology.
Vigilance at point of care:

While the possibilities for adverse drug reactions seem endless, we must be on the lookout for any new medication(s) the
patient might be taking. A thorough, detailed history of all medications must be made in order to elicit any remote possibility
that the drug in question might be the culprit for the side effect. People do not often realize that the common over-the-
counter analgesics – aspirin, Tylenol, Advil, Motrin, Naprosyn, and others – are actually medications. Herbals and supple-
ments such as St. John’s wort, ginkgo biloba, and echinacea can be responsible for various hypersensitivity reactions. For
example, St. John’s wort, in particular, interacts adversely with SSRIs and tricyclic antidepressants.
Contents of the book, and how to use them

1. The A–Z
The major portion of the manual lists in alphabetical order the 900+ generic drugs, biologics, and supplements, and
the adverse reactions that can arise from their use. An asterisk against the entry title indicates this drug is new to this
edition. If you do not find a drug in the main A–Z listing under the name you know it by, you can turn to the concord-
ance of synonyms and trade names to find the generic name it will be listed under. Occasionally a drug has been
omitted from the listing but a cross-reference will link to the profile found in our website database
(www.drugeruptiondata.com).
vi
Trade (Brand) name(s) are then listed alphabetically. When there are many trade names, the ten (or so) most
commonly recognized ones are listed.
Following the trade names is – in parentheses – the latest name of the pharmaceutical company that markets the drug.
Many of the names of the companies have changed from earlier editions of this manual because of acquisitions,
mergers, and other factors in the pharmaceutical industry.
Next appear the Indication(s), the Class in which the drug belongs, and the Half-life of each drug, where known.
Drug interactions: many severe, hazardous drug–drug interactions are recorded. Only clinically significant drug inter-
actions that have been reported to trigger potential harm and that could be life threatening have been included here in
the profile. These interactions are predictable and well documented in controlled studies; they should be avoided.
Pregnancy category: for new drugs approved on or after 30 June, 2015 this field gives (where available) a brief sum-
mary of the full statement reflecting the risk for pregnant women as given in the prescribing guidelines; health care
providers are advised to check the individual label where necessary.
An explanation of the categories for older drugs (A, B, C, D and X) can be found on our website
www.drugeruptiondata.com.
Adverse Drug Reactions: under each drug profile is a list of related ADRs. These adverse events have been classified
under the following categories: Skin, Hair, Nails, Mucosal, Cardiovascular, Central Nervous System,
Neuromuscular/Skeletal, Gastrointestinal/Hepatic, Respiratory, Endocrine/Metabolic, Genitourinary,
Renal, Hematologic, Otic, Ocular, Local, Other.
Within each category, the reactions are listed alphabetically. Thus, the order of listing does not reflect severity or
frequency in any way.
The terminology used to list reaction patterns has been simplified as far as possible by eliminating, for the most part,
tags such as “like” (as in “-Psoriasis-like”), “-reactivation,” “-syndrome,” “-dissemination,” “-iform,” etc.
The number of reports is given for each reaction in square brackets. The incidence of the most important reactions is
given in parentheses where indicated (usually from the full prescribing information for the relevant drug). For
example, the profile for Amoxicillin begins:
Skin
AGEP [28]
Anaphylactoid reactions/Anaphylaxis [15]
Angioedema (<10%) [5]
This means that we have 28 journal articles referring to occurrence of AGEP (acute generalized exanthematous
pustulosis ); 15 articles mentioning the occurrence of anaphylaxis; and 5 articles discussing angioedema, as reactions to
Amoxicillin within the Skin category. All these articles appear on the website www.drugeruptiondata.com together
with links to the article abstracts on PubMed®. Additionally, the incidence of angioedema as a reaction has been
reported as up to 10%.
On some occasions, there are very few adverse reactions to a specific drug. These drugs are still included in the
manual as there is a positive significance in negative findings.
2. Important eruptions / reactions

i) This section of the manual includes a listing of descriptions of important eruption and reaction patterns. Over 40
eruptions/reactions are described here in alphabetical order, from Acanthosis nigricans to Xerostomia.
ii) Following this section are lists of all drugs that have been found to cause these important eruptions/reactions. This
section is a quick look-up tool for drugs that cause important reaction patterns.
(Descriptions of several other reactions, and lists of drugs associated with these reactions, can be found on our
website – www.drugeruptiondata.com.)
iii) We then have a list of the main classes of drugs, from 5-HT1 agonists to Xanthine alkaloids, as a quick reference guide.
iv) There follow lists of the classes of drugs most likely to cause important interactions with other drugs, with the drugs in
those classes.
v) We then have an enlarged section of tables of class reactions, enabling you to see at a glance whether a reaction is
common to all the drugs in that particular class, or to a majority of them, or only to a significant few.
vii
3. The Concordance
The final part of the manual is a concordance to match synonyms (noted in italic) and trade names with the generic
drug name. If you know only the synonym or trade name, you can use this list to find the corresponding generic name
to look up in the main A–Z listing section of the book.
viii
Hypertriglyceridemia (2–6%)
ABACAVIR Renal
ABATACEPT
Trade names: Epzicom (ViiV), Triumeq (ViiV), Fanconi syndrome [2] Trade name: Orencia (Bristol-Myers Squibb)
Trizivir (ViiV), Ziagen (ViiV) Hematologic Indications: Rheumatoid arthritis, juvenile
Indications: HIV infections in combination with Agranulocytosis [3] idiopathic arthritis in pediatric patients 6 years of
other antiretrovirals Neutropenia (2–5%) age and older
Class: Nucleoside analog reverse transcriptase Other Class: Disease-modifying antirheumatic drug
inhibitor Adverse effects [4] (DMARD), T-cell co-stimulation modulator
Half-life: 1.5 hours Infection (5%) Half-life: 1223 days
Clinically important, potentially hazardous Clinically important, potentially hazardous
interactions with: alcohol, arbutamine, interactions with: adalimumab, anakinra,
argatroban, arsenic, darunavir, ganciclovir, certolizumab, denosumab, echinacea, etanercept,
lopinavir, methadone, phenobarbital, phenytoin, ABALOPARATIDE * golimumab, infliximab, lenalidomide, live vaccines,
protease inhibitors, ribavirin, rifampin, tipranavir, natalizumab, pimecrolimus, sipuleucel-T,
valganciclovir Trade name: Tymlos (Radius Health) tacrolimus, TNF antagonists, trastuzumab
Pregnancy category: C Indications: Osteoporosis in postmenopausal Pregnancy category: C
Important contra-indications noted in the women Important contra-indications noted in the
prescribing guidelines for: nursing mothers Class: Parathyroid hormone analog prescribing guidelines for: nursing mothers;
Note: Epzicom is abacavir and lamivudine; Half-life: <2 hours pediatric patients
Triumeq is abacavir, dolutegravir and lamivudine; Clinically important, potentially hazardous
Trizivir is abacavir, lamivudine and zidovudine. interactions with: none known
Pregnancy category: N/A (Not indicated for Skin
Warning: HYPERSENSITIVITY REACTIONS, Basal cell carcinoma [3]
LACTIC ACIDOSIS and SEVERE use in females of reproductive potential)
Important contra-indications noted in the Eczema [2]
HEPATOMEGALY, and EXACERBATIONS OF Herpes simplex (<5%) [3]
HEPATITIS B prescribing guidelines for: pediatric patients
Warning: RISK OF OSTEOSARCOMA Herpes zoster [3]
Hypersensitivity [2]
Skin Malignancies [10]
Anaphylactoid reactions/Anaphylaxis (3%) Cardiovascular Psoriasis [13]
[3] Orthostatic hypotension (<4%) Rash (4%) [6]
Exanthems [2] Palpitation (5%) Sjögren’s syndrome [4]
Hypersensitivity (8–9%) [69] Tachycardia (2%) Squamous cell carcinoma [5]
Lipoatrophy [2] Central Nervous System Vasculitis [2]
Rash (5–7%) [17] Headache (8%) Mucosal
Stevens-Johnson syndrome [2] Vertigo (dizziness) (2–10%) Stomatitis [3]
Toxic epidermal necrolysis [2] Neuromuscular/Skeletal Cardiovascular
Cardiovascular Asthenia (fatigue) (3%) Hypertension (7%) [4]
Myocardial infarction [9] Gastrointestinal/Hepatic Hypotension [2]
Central Nervous System Abdominal pain (3%) Central Nervous System
Abnormal dreams (10%) [2] Nausea (8%) Fever (5%) [2]
Anxiety (5%) Endocrine/Metabolic Headache (5–18%) [6]
Chills (6%) Hypercalcemia (3%) [2] Vertigo (dizziness) (9%) [3]
Depression (6%) Hyperuricemia (25%)
Fever (6%) [2] Neuromuscular/Skeletal
Headache (7–13%) [4] Genitourinary Asthenia (fatigue) [2]
Insomnia [2] Hypercalciuria (11%) Back pain (7%) [2]
Migraine (7%) Urolithiasis (2%) Pain in extremities (3%)
Neuropsychiatric disturbances [3] Local Gastrointestinal/Hepatic
Sleep related disorder (10%) Injection-site edema (10%) Abdominal pain (5%)
Vertigo (dizziness) (6%) [3] Injection-site erythema (58%) Diarrhea (5%) [3]
Neuromuscular/Skeletal Injection-site pain (9%) Dyspepsia (6%)
Asthenia (fatigue) (7–12%) [2] Gastroenteritis [5]
Bone or joint pain (5–6%) Nausea (5%) [2]
Myalgia/Myopathy (5–6%) [2] ABARELIX Vomiting [2]
Gastrointestinal/Hepatic Respiratory
Abdominal pain (6%) See: www.drugeruptiondata.com/drug/id/1011 Bronchitis (<13%) [4]
Diarrhea (7%) [2] Cough (5–8%)
Gastritis (6%) Influenza (5–13%) [2]
Hepatotoxicity [4] Nasopharyngitis (12%) [6]
Nausea (7–19%) [5] Pharyngitis [3]
Vomiting (2–10%) Pneumonia (<5%) [7]
Pulmonary toxicity [2]
Respiratory Rhinitis (<5%) [2]
Bronchitis (4%) Sinusitis (5–13%) [3]
Cough [2] Tuberculosis [2]
Pneumonia (4%) Upper respiratory tract infection (>10%)
Endocrine/Metabolic [9]
ALT increased (6%) Genitourinary
AST increased (6%) Urinary tract infection (5–13%) [10]
Hyperamylasemia (2–4%)
Litt’s Drug Eruption & Reaction Manual B 2018 by Taylor & Francis Group, LLC 1
ABATACEPT See all our books at www.crcpress.com
Local Hematologic Genitourinary

Infusion-related reactions [4] Anemia (25%) [3] Nocturia (6%)
Infusion-site reactions (9%) [5] Leukopenia (17%) [4] Urinary frequency (7%)
Injection-site erythema [3] Neutropenia (37%) [5] Urinary tract infection (12%) [2]
Injection-site hematoma [2] Thrombocytopenia (20%) [3] Hematologic
Injection-site pain [3] Other Anemia [5]
Injection-site pruritus [2] Infection (31%) Thrombocytopenia [2]
Injection-site reactions (3%) [8]
Other
Other Adverse effects [7]
Adverse effects [24]
Death [2]
ABIRATERONE
Infection (36–54%) [25] Trade name: Zytiga (Janssen Biotech)
Indications: Metastatic castration-resistant
ACAMPROSATE
prostate cancer (in combination with prednisone) See: www.drugeruptiondata.com/drug/id/1047
ABCIXIMAB Class: CYP17 inhibitor, Enzyme inhibitor
Half-life: 12 hours
See: www.drugeruptiondata.com/drug/id/2 Clinically important, potentially hazardous
interactions with: atazanavir, carbamazepine, ACARBOSE
clarithromycin, CYP3A4 inhibitors or inducers,
Trade names: Glucobay (Bayer), Precose
ABEMACICLIB * indinavir, itraconazole, ketoconazole, nefazodone,
nelfinavir, phenobarbital, phenytoin, rifabutin, (Bayer)
rifampin, rifapentine, ritonavir, saquinavir, Indications: Non-insulin dependent diabetes
Trade name: Verzenio (Lilly) Type II
Indications: Hormone receptor-positive, human telithromycin, thioridazine, voriconazole
Pregnancy category: X Class: Alpha-glucosidase inhibitor, Antidiabetic
epidermal growth factor 2-negative advanced or Half-life: 2 hours
metastatic breast cancer, either as monotherapy Important contra-indications noted in the
prescribing guidelines for: nursing mothers; Clinically important, potentially hazardous
or in combination with fulvestrant interactions with: alcohol, anabolic steroids,
Class: Kinase inhibitor pediatric patients
Note: Contra-indicated in women who are or beta blockers, cholestyramine, corticosteroids,
Half-life: 18 hours diazoxide, digoxin, diuretics, estrogens,
Clinically important, potentially hazardous may become pregnant.
hypoglycemic agents, MAO inhibitors, neomycin,
interactions with: grapefruit juice, orlistat, pancreatin, pegvisomant, pramlintide,
ketoconazole, strong CYP3A4 inducers and Skin progestogens, somatropin, testosterone
inhibitors Edema (27%) [19] Pregnancy category: B
Pregnancy category: N/A (Can cause fetal Hot flashes (19%) [3] Important contra-indications noted in the
harm) Cardiovascular prescribing guidelines for: nursing mothers;
Important contra-indications noted in the Arrhythmias (7%) pediatric patients
prescribing guidelines for: nursing mothers; Atrial fibrillation [3] Note: Contra-indicated in patients with diabetic
pediatric patients Cardiac failure (2%) ketoacidosis or cirrhosis; also in patients with
Cardiotoxicity [4] inflammatory bowel disease, colonic ulceration,
Hair Chest pain (4%) partial intestinal obstruction or in patients
Alopecia (12%) Hypertension (9%) [23] predisposed to intestinal obstruction.
Mucosal Tachycardia [3]
Stomatitis (14%) Central Nervous System Skin
Xerostomia (17%) Headache [2] AGEP [2]
Central Nervous System Neuromuscular/Skeletal Gastrointestinal/Hepatic
Anorexia [3] Arthralgia [5] Abdominal distension [2]
Dysgeusia (taste perversion) (12%) Asthenia (fatigue) [11] Abdominal pain (19%)
Fever (11%) Back pain [4] Diarrhea (31%)
Headache (20%) Bone or joint pain (30%) [8] Flatulence (74%) [3]
Vertigo (dizziness) (11%) Myalgia/Myopathy (26%) Hepatitis [2]
Neuromuscular/Skeletal Pain in extremities [2] Hepatotoxicity [3]
Arthralgia (15%) Rhabdomyolysis [2] Pneumatosis intestinalis [8]
Asthenia (fatigue) (65%) [7] Gastrointestinal/Hepatic Other
Gastrointestinal/Hepatic Constipation [7] Adverse effects [5]
Abdominal pain (39%) [2] Diarrhea (18%) [5]
Constipation (17%) Dyspepsia (6%)
Diarrhea (90%) [7] Hepatotoxicity (2%) [12]
Nausea [8]
ACEBUTOLOL
Nausea (64%) [7]
Vomiting (35%) [4] Respiratory See: www.drugeruptiondata.com/drug/id/4
Respiratory Cough (11%)
Cough (19%) Dyspnea [2]
Endocrine/Metabolic
Upper respiratory tract infection (5%) [2] ACECLOFENAC
ALT increased (31%) Endocrine/Metabolic
Appetite decreased (45%) [2] ALT increased (11%) [5] See: www.drugeruptiondata.com/drug/id/1261
AST increased (30%) AST increased (31%) [3]
Dehydration (10%) Hypercholesterolemia [2]
Serum creatinine increased (13%) [3] Hypertriglyceridemia (63%)
Weight loss (14%) [2] Hypokalemia [21]
2 Litt’s Drug Eruption & Reaction Manual B 2018 by Taylor & Francis Group, LLC
Litt’s Drug Eruption & Reaction Manual ACIPIMOX
Headache [IV] (10%) [5] Vomiting [2]

ACEMETACIN Insomnia [IV] (7%) Endocrine/Metabolic
Somnolence (drowsiness) [8] Acidosis [3]
See: www.drugeruptiondata.com/drug/id/1691 Vertigo (dizziness) [15] Libido decreased [2]
Neuromuscular/Skeletal Weight loss [2]
Rhabdomyolysis [4] Renal
ACENOCOUMAROL Gastrointestinal/Hepatic Nephrolithiasis [3]
See: www.drugeruptiondata.com/drug/id/1276 Abdominal distension [2] Ocular
Abdominal pain [IV] [3] Choroidal detachment [2]
Constipation [IV] (>5%) [7] Corneal edema [2]
Diarrhea [IV] [2] Glaucoma [3]
ACETAMINOPHEN Hepatotoxicity [70] Myopia [2]
Nausea [IV] (34%) [18]
Synonyms: APAP; paracetamol Pancreatitis [6]
Trade names: Anacin-3 (Wyeth), Darvocet-N Vomiting (15%) [16]
(aaiPharma), Excedrin (Bristol-Myers Squibb),
Respiratory
ACETOHEXAMIDE
Lorcet (Forest), Panadol (GSK), Percocet (Endo),
Tylenol (Ortho-McNeil), Vicodin (AbbVie) Asthma [3] See: www.drugeruptiondata.com/drug/id/7
Indications: Pain, fever Pulmonary toxicity [IV] (>5%)
Class: Analgesic, non-narcotic Endocrine/Metabolic
Half-life: <3 hours
Clinically important, potentially hazardous
Acidosis [3] ACETYLCHOLINE
Renal
interactions with: alcohol, anticonvulsants, Nephrotoxicity [9] See: www.drugeruptiondata.com/drug/id/2445
barbiturates, busulfan, carbamazepine, Renal failure [3]
cholestyramine, conivaptan, coumarins,
didanosine, dong quai, exenatide, imatinib, Hematologic
isoniazid, liraglutide, melatonin, metoclopramide, Thrombocytopenia [2] ACETYLCYSTEINE
metyrapone, PEG-interferon, pramlintide, Other
probenecid, St John’s wort Adverse effects [16] Synonyms: N-acetylcysteine; L-Cysteine; NAC
Pregnancy category: C Death [6] Indications: Emphysema, bronchitis,
Important contra-indications noted in the tuberculosis, bronchiectasis, tracheostomy care,
prescribing guidelines for: nursing mothers antidote for acetaminophen toxicity
Note: Acetaminophen is the active metabolite of Class: Antidote, Antioxidant
phenacetin. [IV] = intravenous. As a general point
ACETAZOLAMIDE Half-life: N/A
most reactions listed are those that have Clinically important, potentially hazardous
Trade name: Diamox (Duramed) interactions with: carbamazepine, nitroglycerin
developed following the normal prescribing doses Indications: Epilepsy, glaucoma
for acetaminophen and the overdosing, poisoning, Pregnancy category: B
Class: Carbonic anhydrase inhibitor, Diuretic Note: As an antidote, it is difficult to differentiate
and other toxicities that have been reported have Half-life: 26 hours
been excluded. side effects due to the drug from those due to the
Clinically important, potentially hazardous effects of the poison.
interactions with: arsenic, aspirin, ephedra,
Skin indacaterol, lisdexamfetamine, lithium,
AGEP [10] metformin, mivacurium, triamcinolone Skin
Anaphylactoid reactions/Anaphylaxis [19] Pregnancy category: C Anaphylactoid reactions/Anaphylaxis (8–
Angioedema [8] Important contra-indications noted in the 18%) [13]
Dermatitis [3] prescribing guidelines for: the elderly; nursing Angioedema [6]
Erythema [3] mothers; pediatric patients Pruritus (<4%) [3]
Erythema multiforme [3] Note: Acetazolamide is a sulfonamide and can be Rash (2–4%) [4]
Exanthems [7] absorbed systemically. Sulfonamides can produce Urticaria (6–8%)
Exfoliative dermatitis [2] severe, possibly fatal, reactions such as toxic Cardiovascular
Fixed eruption [41] epidermal necrolysis and Stevens-Johnson Flushing (<8%) [2]
Hyperhidrosis [2] syndrome. Tachycardia (<4%)
Hypersensitivity [12] Central Nervous System
Neutrophilic eccrine hidradenitis [2] Skin Seizures [2]
Pemphigus [2] AGEP [2]
Pruritus [5] Gastrointestinal/Hepatic
Anaphylactoid reactions/Anaphylaxis [3] Diarrhea [2]
Purpura [6] Exanthems [2]
Rash [IV] [2] Nausea (<6%) [3]
Pemphigus [2] Vomiting (2–10%) [2]
Stevens-Johnson syndrome [10] Stevens-Johnson syndrome [6]
Toxic epidermal necrolysis [13] Toxic epidermal necrolysis [2] Other
Urticaria [17] Adverse effects [2]
Vasculitis [4] Central Nervous System Death [2]
Depression [2]
Mucosal Dysgeusia (taste perversion) (>10%) [8]
Xerostomia [3] Paresthesias [6]
Cardiovascular Neuromuscular/Skeletal
ACIPIMOX
Hypertension [IV] [3] Asthenia (fatigue) [4]
Hypotension [2] See: www.drugeruptiondata.com/drug/id/1343
Gastrointestinal/Hepatic
Central Nervous System Diarrhea [2]
Agitation [IV] (>5%) Dyspepsia [2]
Fever [IV] (5%) Nausea [2]
ACITRETIN Over 100 updates per week on www.drugeruptiondata.com
Gingivitis (<10%) Other

ACITRETIN Mucocutaneous reactions [3] Adverse effects [9]
Sialorrhea (<10%) Dipsia (thirst) (<10%)
Trade names: Neotigason (Actavis), Soriatane Stomatitis (<10%) [2] Infection [2]
(Stiefel) Tongue disorder (<10%) Side effects [4]
Indications: Psoriasis Ulcerative stomatitis (<10%) Teratogenicity [7]
Class: Retinoid Xerostomia (1060%) [7]
Half-life: 49 hours
Clinically important, potentially hazardous Cardiovascular
interactions with: alcohol, bexarotene, Capillary leak syndrome [2] ACLIDINIUM
chloroquine, cholestyramine, corticosteroids, Central Nervous System
coumarins, danazol, demeclocycline, doxycycline, Anorexia (<10%) See: www.drugeruptiondata.com/drug/id/3007
ethanolamine, isotretinoin, lithium, lymecycline, Depression (<10%) [4]
medroxyprogesterone, methotrexate, Dysgeusia (taste perversion) (<10%)
minocycline, oxytetracycline, phenytoin, Headache (<10%) [2] ACYCLOVIR
progestins, St John’s wort, tetracycline, Hyperesthesia (1025%)
tigecycline, vitamin A Insomnia (<10%) Synonyms: aciclovir; ACV; acycloguanosine
Pregnancy category: X Neurotoxicity [3] Trade names: Sitavig (Cipher), Zovirax (GSK)
Important contra-indications noted in the Pain (<10%) Indications: Herpes simplex, herpes zoster
prescribing guidelines for: nursing mothers; Paralysis (facial) (<10%) Class: Antiviral, Antiviral, topical, Guanine
pediatric patients Paresthesias (1025%) [2] nucleoside analog
Note: Oral retinoids can cause birth defects, and Pseudotumor cerebri [5] Half-life: 3 hours (adults)
women should avoid acitretin when pregnant or Rigors (10–25%) [2] Clinically important, potentially hazardous
trying to conceive. Somnolence (drowsiness) (<10%) interactions with: cobicistat/elvitegravir/
Warning: PREGNANCY Stroke [2] emtricitabine/tenofovir alafenamide, cobicistat/
Suicidal ideation [2] elvitegravir/emtricitabine/tenofovir disoproxil,
Skin Neuromuscular/Skeletal meperidine, tenofovir disoproxil
Angioedema [2] Arthralgia (10–25%) [2] Pregnancy category: B
Atrophy (1025%) Asthenia (fatigue) (<10%) [3] Important contra-indications noted in the
Bromhidrosis (<10%) Back pain (<10%) prescribing guidelines for: nursing mothers
Bullous dermatitis (<10%) Bone or joint pain [2]
Clammy skin (<10%) Hyperostosis [10] Skin
Dermatitis (<10%) Myalgia/Myopathy [4] Acneform eruption (<3%)
Diaphoresis (<10%) [2] Osteoporosis [2] Dermatitis [12]
Edema (<10%) Gastrointestinal/Hepatic Exanthems (<5%) [5]
Erythema (18%) Abdominal pain (<10%) Facial edema (3–5%)
Erythroderma [3] Diarrhea (<10%) [2] Peripheral edema [2]
Exanthems (10–25%) [2] Hepatitis [5] Pruritus (<10%)
Exfoliative dermatitis (2550%) [3] Hepatotoxicity [8] Radiation recall dermatitis [2]
Fissures (<10%) Nausea (<10%) [2] Rash (<3%) [3]
Hot flashes (<10%) Pancreatitis [3] Urticaria (<5%) [4]
Hyperhidrosis (<10%) [2] Vomiting [2] Hair
Palmar–plantar desquamation (2080%) [7] Alopecia (<3%)
Photosensitivity [3] Respiratory
Pigmentation [3] Laryngitis [2] Central Nervous System
Pruritus (1050%) [10] Rhinitis (25–50%) [2] Headache (2%) [4]
Psoriasis (aggravated) (<10%) Sinusitis (<10%) Neurotoxicity [8]
Purpura (<10%) Endocrine/Metabolic Neuromuscular/Skeletal
Rash (>10%) GGT increased [2] Asthenia (fatigue) (12%)
Seborrhea (<10%) Hyperbilirubinemia [2] Gastrointestinal/Hepatic
Stickiness (350%) [7] Hypercholesterolemia (25–50%) [3] Diarrhea (2–3%)
Sunburn (<10%) Hyperlipidemia [5] Nausea (2–5%) [3]
Toxicity [3] Hypertriglyceridemia (50–75%) [4] Vomiting (3%)
Ulcerations (<10%) Genitourinary
Xerosis (2550%) [14] Renal
Vulvovaginal candidiasis [2] Nephrotoxicity [12]
Hair Otic Renal failure [4]
Alopecia (1075%) [21] Ear pain (<10%)
Curly hair [3] Ocular
Tinnitus (<10%) Hallucinations, visual [2]
Hair changes (<10%)
Hair pigmentation [2] Ocular Periorbital edema (3–5%)
Blepharitis (<10%) Local
Nails Cataract (<10%)
Brittle nails [3] Injection-site inflammation (>10%)
Conjunctivitis (<10%) [2] Injection-site thrombophlebitis (9%)
Nail changes (2550%) Diplopia (<10%)
Paronychia (1025%) [6] Night blindness (<10%) [2] Other
Pyogenic granuloma (<10%) [4] Ocular adverse effects [2] Adverse effects [2]
Mucosal Ocular itching [2]
Cheilitis (>75%) [14] Ocular pain (<10%)
Dry mucous membranes [4] Photophobia (<10%) [2]
Epistaxis (nosebleed) (10–25%) [2] Vision blurred (<10%)
Gingival bleeding (<10%) Xerophthalmia (10–25%) [3]
Litt’s Drug Eruption & Reaction Manual ADEFOVIR
Chest pain (<5%) Sepsis [2]

ADALIMUMAB Congestive heart failure (<5%) Ocular
Hypertension (<5%) Cataract (<5%)
Trade names: Amjevita (Amgen), Humira Myocardial infarction (<5%)
(AbbVie) Optic neuritis [5]
Palpitation [2] Uveitis [4]
Indications: Rheumatoid arthritis, polyarticular Pericarditis (<5%)
juvenile idiopathic arthritis, psoriatic arthritis, Tachycardia (<5%) Local
ankylosing spondylitis, Crohn’s disease, ulcerative Thromboembolism [2] Injection-site edema (15%) [2]
colitis, psoriasis Injection-site erythema (15%) [3]
Class: Cytokine inhibitor, Disease-modifying Central Nervous System Injection-site pain (12%)
antirheumatic drug (DMARD), Monoclonal Aseptic meningitis [2] Injection-site reactions [26]
antibody, TNF inhibitor Confusion (<5%)
Encephalitis [2] Other
Half-life: 1020 days Adverse effects [45]
Clinically important, potentially hazardous Fever (<5%) [3]
Guillain–Barré syndrome [5] Death [8]
interactions with: abatacept, anakinra, live Infection (5%) [70]
vaccines Headache (12%) [6]
Leukoencephalopathy [3] Side effects [2]
Pregnancy category: B
Important contra-indications noted in the Multiple sclerosis (<5%) [3]
prescribing guidelines for: nursing mothers Neurotoxicity [3]
Note: TNF inhibitors should be used in patients Paresthesias (<5%) [2] ADAPALENE
with heart failure only after consideration of other Syncope (<5%)
treatment options. TNF inhibitors are contra- Tremor (<5%) Trade names: Differin (Galderma), Epiduo
indicated in patients with a personal or family Vertigo (dizziness) [2] (Galderma)
history of multiple sclerosis or demyelinating Neuromuscular/Skeletal Indications: Acne vulgaris
disease. TNF inhibitors should not be Arthralgia (<5%) [6] Class: Retinoid
administered to patients with moderate to severe Asthenia (fatigue) [2] Half-life: N/A
heart failure (New York Heart Association Back pain (6%) [3] Clinically important, potentially hazardous
Functional Class III/IV). Tuberculous arthritis [2] interactions with: resorcinol, salicylates
Warning: SERIOUS INFECTIONS AND Pregnancy category: C
Gastrointestinal/Hepatic Important contra-indications noted in the
MALIGNANCY Abdominal pain (7%) [2] prescribing guidelines for: nursing mothers;
Cholecystitis (<5%) pediatric patients
Skin Colitis [2] Note: Epiduo is adapalene and benzoyl peroxide.
Acneform eruption [3] Esophagitis (<5%)
Angioedema [3] Gastroenteritis (<5%)
Carcinoma [2] Hepatitis [7] Skin
Cellulitis (<5%) [2] Hepatotoxicity [10] Burning (38%) [7]
Dermatomyositis [5] Nausea (9%) [2] Erythema (38%) [9]
Eczema [2] Vomiting (<5%) Pruritus (>10%) [11]
Erysipelas (<5%) Scaling (44%) [6]
Respiratory Stinging (38%) [3]
Granulomatous reaction [5] Asthma (<5%)
Henoch–Schönlein purpura [2] Xerosis (45%) [10]
Bronchitis [2]
Herpes zoster [10] Bronchospasm (<5%) Other
Hidradenitis [2] Dyspnea (<5%) Adverse effects [3]
Hypersensitivity [3] Flu-like syndrome (7%)
Lesions [2] Nasopharyngitis [4]
Lichenoid eruption [5] Pleural effusion (<5%) ADEFOVIR
Lupus erythematosus [16] Pneumonia (<5%) [6]
Lupus syndrome [3] Pneumonitis [3] Trade name: Hepsera (Gilead)
Lymphoma [8] Pulmonary fibrosis [3] Indications: HIV infection, hepatitis B infection
Malignancies [4] Pulmonary toxicity [7] Class: Antiretroviral, Nucleotide analog reverse
Melanoma [6] Sinusitis (11%) [2] transcriptase inhibitor
Neoplasms [2] Tuberculosis [9] Half-life: 1618 hours
Palmoplantar pustulosis [3] Upper respiratory tract infection (17%) [8] Clinically important, potentially hazardous
Peripheral edema (<5%) interactions with: amikacin, amphotericin B,
Pruritus [6] Endocrine/Metabolic
Creatine phosphokinase increased (<5%) cobicistat/elvitegravir/emtricitabine/tenofovir
Psoriasis [39] disoproxil, delavirdine, drugs causing kidney
Rash (12%) [4] Hypercholesterolemia (6%)
toxicity, foscarnet, gentamicin, hydroxyurea,
Sarcoidosis [8] Genitourinary pentamidine, tenofovir disoproxil, tobramycin
Squamous cell carcinoma [5] Cystitis (<5%) Pregnancy category: C
Stevens-Johnson syndrome [2] Hematuria (5%) Important contra-indications noted in the
Urticaria [3] Pelvic pain (<5%) prescribing guidelines for: the elderly; nursing
Vasculitis [9] Urinary tract infection (8%) mothers; pediatric patients
Vitiligo [2] Renal Warning: SEVERE ACUTE EXACERBATIONS
Hair Nephrotoxicity [2] OF HEPATITIS, NEPHROTOXICITY, HIV
Alopecia [5] Hematologic RESISTANCE, LACTIC ACIDOSIS AND SEVERE
Alopecia areata [7] Agranulocytosis (<5%) HEPATOMEGALY WITH STEATOSIS
Alopecia universalis [2] Eosinophilia [3]
Cardiovascular Hemolytic anemia [2] Skin
Arrhythmias (<5%) Leukopenia (<5%) Pruritus (<10%)
Cardiac arrest (<5%) Pancytopenia [2] Rash (<10%)
ADEFOVIR See all our books at www.crcpress.com
Central Nervous System Other Hypokalemia (10%) [3]

Headache (9%) [2] Adverse effects [2] Genitourinary
Pain [2] Urinary tract infection (9%)
Neuromuscular/Skeletal Hematologic
Asthenia (fatigue) (13%) [3] ADO-TRASTUZUMAB Anemia (14%) [6]
Back pain (<10%) Febrile neutropenia [3]
Osteomalacia [6] EMTANSINE Hemorrhage (32%) [2]
Gastrointestinal/Hepatic Neutropenia (7%) [4]
Synonym: T-DM1
Abdominal pain (9%) Thrombocytopenia (31%) [23]
Trade name: Kadcyla (Genentech)
Diarrhea (3%) Indications: HER2-positive, metastatic breast Ocular
Dyspepsia (3%) cancer in patients who previously received Conjunctivitis (4%)
Flatulence (4%) trastuzumab and a taxane, separately or in Lacrimation (3%)
Hepatotoxicity (<25%) combination Vision blurred (5%)
Nausea (5%) Class: Antibody drug conjugate (ADC), HER2- Xerophthalmia (4%)
Vomiting (<10%) targeted antibody-drug conjugate Other
Respiratory Half-life: 4 days Adverse effects [5]
Cough (6–8%) Clinically important, potentially hazardous Death [3]
Rhinitis (<5%) interactions with: none known
Endocrine/Metabolic Pregnancy category: D
Important contra-indications noted in the
Hypophosphatemia [5]
prescribing guidelines for: nursing mothers; AFAMELANOTIDE
Genitourinary pediatric patients
Hematuria (11%) See: www.drugeruptiondata.com/drug/id/1315
Warning: HEPATOTOXICITY, CARDIAC
Renal TOXICITY, EMBRYO-FETAL TOXICITY
Fanconi syndrome [11]
Nephrotoxicity [14] Skin AFATINIB
Hypersensitivity (2%)
Trade name: Gilotrif (Boehringer Ingelheim)
Peripheral edema (7%)
Indications: Metastatic non-small cell lung cancer
ADENOSINE Pruritus (6%)
in patients whose tumors have epidermal growth
Rash (12%)
factor receptor exon 19 deletions or exon 21
Synonym: ATP Telangiectasia [2]
(L858R) substitution mutations, metastatic
Trade names: Adenocard (Astellas), Adenocur Mucosal squamous non-small cell lung cancer progressing
(Sanofi-Aventis) Epistaxis (nosebleed) (23%) following platinium-based chemotherapy
Indications: Paroxysmal supraventricular Stomatitis (14%) Class: Tyrosine kinase inhibitor
tachycardia, varicose vein complications with Xerostomia (17%) Half-life: 37 hours
stasis dermatitis
Cardiovascular Clinically important, potentially hazardous
Class: Antiarrhythmic class IV, Neurotransmitter
Cardiotoxicity [2] interactions with: amiodarone, carbamazepine,
Half-life: <10 seconds
Hypertension (5%) cyclosporine, erythromycin, itraconazole,
ketoconazole, nelfinavir, P-glycoprotein inhibitors,
interactions with: aminophylline, Central Nervous System
phenobarbital, phenytoin, quinidine, rifampin,
antiarrhythmics, beta blockers, bupivacaine, Chills (8%)
ritonavir, saquinavir, St John’s wort, tacrolimus,
carbamazepine, dipyridamole, levobupivacaine, Dysgeusia (taste perversion) (8%)
verapamil
nicotine, prilocaine, QT prolonging agents, Fever (19%) [2]
Pregnancy category: D
ropivacaine Headache (28%) [4]
Pregnancy category: C Insomnia (12%)
prescribing guidelines for: nursing mothers;
Important contra-indications noted in the Peripheral neuropathy (21%)
pediatric patients
prescribing guidelines for: pediatric patients Vertigo (dizziness) (10%)
Neuromuscular/Skeletal
Cardiovascular Skin
Arthralgia (19%) [3]
Arrhythmias [2] Acneform eruption [25]
Asthenia (fatigue) (18–36%) [12]
Atrial fibrillation [6] Fissures [2]
Bone or joint pain (36%)
Chest pain [5] Hand–foot syndrome [2]
Myalgia/Myopathy (14%)
Coronary vasospasm [2] Pruritus [2]
Gastrointestinal/Hepatic Rash [49]
Flushing (18–44%) Abdominal pain (19%)
Torsades de pointes [2] Toxicity [3]
Constipation (27%) [3] Xerosis [6]
Central Nervous System Diarrhea (24%) [5]
Headache (2–18%) [2]
Nails
Dyspepsia (9%)
Vertigo (dizziness) (2–12%) Nail changes [2]
Hepatotoxicity [14]
Paronychia (58%) [10]
Neuromuscular/Skeletal Nausea (40%) [9]
Jaw pain (<15%) Vomiting (19%) Mucosal
Epistaxis (nosebleed) [3]
Gastrointestinal/Hepatic Respiratory
Mucosal inflammation [7]
Abdominal pain (13%) Cough (18%)
Mucositis [10]
Dyspnea (12%)
Respiratory Rhinorrhea (11%)
Pneumonia [3]
Cough (6–8%) Stomatitis (71%) [19]
Dyspnea [3] Endocrine/Metabolic
Central Nervous System
Respiratory distress (11%) ALP increased (5%)
Anorexia [3]
ALT increased (82%) [3]
Fever (12%)
AST increased (98%) [6]
Litt’s Drug Eruption & Reaction Manual ALBIGLUTIDE
Neuromuscular/Skeletal Gastrointestinal perforation [4] Gastrointestinal/Hepatic

Asthenia (fatigue) [17] Respiratory Abdominal pain (<7%) [7]
Gastrointestinal/Hepatic Dysphonia [5] Hepatitis [4]
Diarrhea (96%) [65] Dyspnea [2] Nausea (4–6%) [3]
Dysphagia [2] Pulmonary embolism [2] Vomiting (4–6%) [2]
Hepatotoxicity (10%) [5] Endocrine/Metabolic Other
Nausea [15] Weight loss [2] Adverse effects [5]
Vomiting [10]
Renal
Respiratory Proteinuria [8]
Dyspnea [3]
Hematologic
ALBIGLUTIDE
Pneumonitis [2]
Pulmonary toxicity [5] Hemorrhage [3] Trade name: Tanzeum (GSK)
Neutropenia [10] Indications: To improve glycemic control in
Endocrine/Metabolic
ALT increased [2] Ocular adults with Type II diabetes mellitus
Appetite decreased (29%) [5] Cataract (7%) [2] Class: Glucagon-like peptide-1 (GLP-1) receptor
Dehydration [3] Conjunctival hemorrhage (25%) [2] agonist
Hypokalemia [2] Conjunctival hyperemia (4%) Half-life: 5 days
Corneal erosion (4%) Clinically important, potentially hazardous
Hematologic Intraocular pressure increased (5%) [2] interactions with: none known
Anemia [3] Lacrimation (3%) Pregnancy category: C
Febrile neutropenia [2] Ocular adverse effects [3] Important contra-indications noted in the
Leukopenia [2] Ocular pain (3–9%) prescribing guidelines for: nursing mothers;
Neutropenia [6] Vision blurred (2%) pediatric patients
Thrombocytopenia [2] Vitreous detachment (6%) Note: Contra-indicated in patients with a
Other Vitreous floaters (6%) personal or family history of medullary thyroid
Adverse effects [7] Local carcinoma or in patients with multiple endocrine
Death [4] Injection-site pain (3%) neoplasia syndrome Type 2.
Warning: RISK OF THYROID C-CELL TUMORS
Other
Adverse effects [2]
AFLIBERCEPT Death [2] Central Nervous System
Infection [2] Headache [4]
Synonym: ziv-aflibercept Vertigo (dizziness) [2]
Trade names: Eylea (Regeneron), Zaltrap Neuromuscular/Skeletal
(Sanofi-Aventis) Arthralgia (7%)
Indications: Neovascular (wet) age-related AGALSIDASE Back pain (7%) [2]
macular degeneration (Eylea), metastatic
colorectal cancer (Zaltrap) in combination with See: www.drugeruptiondata.com/drug/id/993 Gastrointestinal/Hepatic
FOLFIRI (fluorouracil, leucovorin and irinotecan) Constipation [2]
Class: Fusion protein Diarrhea (13%) [15]
Half-life: terminal 5–6 days ALBENDAZOLE Dyspepsia (3%)
Gastroesophageal reflux (4%)
interactions with: none known Trade name: Albenza (GSK) Nausea (11%) [20]
Pregnancy category: C Indications: Nematode infections, hydatid cyst Pancreatitis [4]
Important contra-indications noted in the disease Vomiting (4%) [15]
prescribing guidelines for: nursing mothers; Class: Anthelmintic Respiratory
pediatric patients Half-life: 812 hours Cough (7%)
Note: Eylea: Contra-indicated in patients with Clinically important, potentially hazardous Influenza (5%)
ocular or periocular infection or active intraocular interactions with: antimalarials, conivaptan, Nasopharyngitis [3]
inflammation. dexamethasone, high fat foods Pneumonia (2%)
Warning: Zaltrap: HEMORRHAGE, Pregnancy category: C Sinusitis (6%)
GASTROINTESTINAL PERFORATION, Important contra-indications noted in the Upper respiratory tract infection (14%) [4]
COMPROMISED WOUND HEALING prescribing guidelines for: nursing mothers Endocrine/Metabolic
GGT increased (2%)
Mucosal Skin Hypoglycemia (2%) [5]
Epistaxis (nosebleed) [3] Fixed eruption [2] Local
Stomatitis [6] Pruritus [4] Injection-site hematoma (2%)
Cardiovascular Urticaria [2] Injection-site reactions (11%) [15]
Hypertension [12] Hair Other
Myocardial infarction (<2%) Alopecia (reversible) (<2%) [4] Adverse effects [4]
Venous thromboembolism [2] Central Nervous System
Central Nervous System Fever (<2%)
Anorexia [2] Headache (<11%) [5]
Headache [2] Intracranial pressure increased (<2%)
Stroke (<2%) Psychosis [2]
Neuromuscular/Skeletal Vertigo (dizziness) (<2%) [2]
Asthenia (fatigue) [6] Neuromuscular/Skeletal
Gastrointestinal/Hepatic Dystonia [3]
Diarrhea [5]
ALBUTEROL Over 100 updates per week on www.drugeruptiondata.com
busulfan, captopril, carboplatin, carmustine, Depression [3]

ALBUTEROL chlorambucil, ciclesonide, cilazapril, cisplatin, Dysgeusia (taste perversion) (7%)
corticosteroids, cyclophosphamide, cytarabine, Fever (29%) [8]
Synonym: salbutamol dacarbazine, dactinomycin, daunorubicin, Neurotoxicity [3]
Trade names: AccuNeb (Mylan Specialty), docetaxel, doxorubicin, enalapril, estramustine, Pain (12%)
Combivent (Boehringer Ingelheim), Duoneb etoposide, fludarabine, fluorouracil, fosinopril, Rigors [3]
(Mylan Specialty), Proventil (Schering), Ventolin gemcitabine, gentamicin, hydroxyurea, idarubicin, Somnolence (drowsiness) (22%)
(GSK), Volmax (Muro) ifosfamide, indomethacin, interferon alfa, Vertigo (dizziness) (11%)
Indications: Bronchospasm associated with irbesartan, kanamycin, levamisole, lisinopril,
asthma Neuromuscular/Skeletal
lomustine, mechlorethamine, melphalan, Asthenia (fatigue) (23–27%)
Class: Beta-2 adrenergic agonist, Bronchodilator, mercaptopurine, methotrexate, mitomycin,
Tocolytic Myalgia/Myopathy (6%)
mitotane, mitoxantrone, neomycin, olmesartan, Myasthenia gravis [2]
Half-life: 36 hours PEG-interferon, pentostatin, plicamycin,
Clinically important, potentially hazardous procarbazine, quinapril, ramipril, streptomycin, Gastrointestinal/Hepatic
interactions with: atomoxetine, epinephrine, streptozocin, thioguanine, thiotepa, tobramycin, Abdominal pain (11%)
insulin degludec, insulin detemir, insulin glargine, trandolapril, tretinoin, triamcinolone, uracil, Diarrhea (67%) [3]
insulin glulisine vinblastine, vincristine, vinorelbine Hepatotoxicity [2]
Pregnancy category: C Pregnancy category: C Nausea (35%) [9]
Important contra-indications noted in the Important contra-indications noted in the Vomiting (50%) [6]
prescribing guidelines for: nursing mothers prescribing guidelines for: nursing mothers; Respiratory
Note: Combivent is albuterol and ipratropium. pediatric patients Cough (11%)
Note: Contra-indicated in patients with Dyspnea (43%)
Skin significant cardiac, pulmonary, renal, hepatic, or Pulmonary toxicity (11–24%) [2]
Dermatitis [2] CNS impairment. Rhinitis (10%)
Diaphoresis (<10%) Warning: CAPILLARY LEAK SYNDROME Endocrine/Metabolic
Erythema (palmar) (with infusion) [2] Acidosis (12%)
Mucosal Skin ALP increased (10%)
Xerostomia (<10%) Angioedema [2] AST increased (23%)
Cardiovascular Dermatitis [2] Creatine phosphokinase increased (33%) [2]
Flushing (<10%) Edema (47%) [3] Hypocalcemia (11%)
Hypertension [2] Erythema (41%) [5] Hypomagnesemia [2]
Myocardial infarction [2] Erythema nodosum [3] Hypophosphatemia [2]
Palpitation [2] Erythroderma [4] Weight gain (16%)
Tachyarrhythmia [2] Exanthems [5] Weight loss [2]
Tachycardia [2] Exfoliative dermatitis (18%) Genitourinary
Linear IgA bullous dermatosis [4] Oliguria (63%)
Central Nervous System Necrosis [2]
Dysgeusia (taste perversion) (<10%) Pemphigus [2] Renal
Tremor [2] Peripheral edema (28%) Nephrotoxicity [4]
Respiratory Petechiae (4%) Hematologic
Dyspnea [2] Pruritus (24%) [7] Anemia (29%)
Psoriasis [4] Leukopenia (16%) [2]
Endocrine/Metabolic
Purpura (4%) Sepsis [3]
Acidosis [3]
Rash (42%) [2] Thrombocytopenia (37%) [2]
Other Scleroderma [2]
Adverse effects [2] Local
Toxic epidermal necrolysis [2]
Injection-site inflammation [2]
Toxicity [6]
Injection-site nodules [2]
Urticaria (2%) [3]
Injection-site reactions (3%) [2]
ALCAFTADINE Vitiligo [3]
Other
Xerosis (15%)
See: www.drugeruptiondata.com/drug/id/1851 Adverse effects [3]
Hair Death [5]
Alopecia [2]
Infection (13%) [2]
Mucosal
ALCLOMETASONE Oral mucosal eruption [2]
Stomatitis (22%)
See: www.drugeruptiondata.com/drug/id/1082 ALECTINIB
Cardiovascular
Arrhythmias (10%) Trade name: Alecensa (Genentech)
Capillary leak syndrome [12] Indications: Anaplastic lymphoma kinase-
ALDESLEUKIN Cardiotoxicity (11%) [2] positive, metastatic non-small cell lung cancer in
Hypotension (71%) [6] patients who have progressed on, or are
Synonyms: IL-2; interleukin-2 Supraventricular tachycardia (12%) intolerant to, crizotinib
Trade name: Proleukin (Chiron) Tachycardia (23%) Class: Kinase inhibitor
Indications: Metastatic renal cell carcinoma and Vascular leak syndrome [6] Half-life: 33 hours
metastatic melanoma Vasodilation (13%) Clinically important, potentially hazardous
Class: Biologic, Immunomodulator, Interleukin-2 interactions with: none known
Half-life: 685 minutes
Anorexia (20%)
Anxiety (12%)
interactions with: acebutolol, alfuzosin,
altretamine, amikacin, aminoglycosides,
Chills (52%)
antineoplastics, betamethasone, bleomycin,
Confusion (34%)
Litt’s Drug Eruption & Reaction Manual ALENDRONATE
Pregnancy category: N/A (Can cause fetal Pneumonia (16%) [3]

harm) ALEMTUZUMAB Pneumonitis [2]
Important contra-indications noted in the Respiratory tract infection [2]
prescribing guidelines for: nursing mothers; Trade names: Campath (Bayer), MabCampath Tuberculosis [2]
pediatric patients (Schering)
Indications: B-cell chronic lymphcyotic Endocrine/Metabolic
leukemia, non-Hodgkin’s lymphoma Hyperthyroidism [2]
Skin Class: Biologic, Immunosuppressant, Monoclonal Hypothyroidism [2]
Edema (30%) antibody Thyroid dysfunction [14]
Peripheral edema [5] Half-life: 12 days Renal
Photosensitivity (10%) [2] Clinically important, potentially hazardous Nephrotoxicity [2]
Rash (18%) [2] interactions with: none known Hematologic
Hair Pregnancy category: C Anemia (76%) [4]
Alopecia [2] Note: Prophylactic therapy against PCP Cytopenia [2]
Central Nervous System pneumonia and herpes viral infections is Hemolytic anemia [2]
Dysgeusia (taste perversion) [2] recommended upon initiation of therapy and for Hemotoxicity [4]
Headache (17%) [2] at least 2 months following last dose. Leukopenia [4]
Warning: CYTOPENIAS, INFUSION Lymphopenia (97%) [2]
Neuromuscular/Skeletal REACTIONS, and INFECTIONS
Asthenia (fatigue) (41%) [5] Neutropenia (77%) [7]
Back pain (12%) Sepsis [2]
Myalgia/Myopathy (29%) [6] Skin Thrombocytopenia (71%) [10]
Carcinoma [2] Local
Gastrointestinal/Hepatic Erythema (4%)
Constipation (34%) [7] Application-site reactions [2]
Herpes [2] Infusion-related reactions [10]
Diarrhea (16%) [2] Herpes simplex [2]
Nausea (18%) [3] Infusion-site reactions [6]
Herpes zoster [3] Injection-site pruritus (3040%)
Vomiting (12%) [2] Lymphoma [2] Injection-site reactions (90%) [5]
Respiratory Lymphoproliferative disease (6470%)
Cough (19%) Peripheral edema (13%) Other
Dyspnea (16%) Pruritus (14–24%) Adverse effects [6]
Pulmonary toxicity [3] Purpura (8%) Death [13]
Rash (13–40%) [5] Infection (43–74%) [51]
Endocrine/Metabolic
ALP increased (47%) [3] Thrombocytopenic purpura [10]
ALT increased (34%) [5] Urticaria (16–30%) [2]
AST increased (51%) [6] Mucosal ALENDRONATE
Creatine phosphokinase increased (43%) [6] Stomatitis (14%)
GGT increased [2] Trade names: Binosto (Mission), Fosamax
Cardiovascular (Merck)
Hyperbilirubinemia (39%) [5] Flushing [2]
Hyperglycemia (36%) Indications: Osteoporosis in postmenopausal
Hypertension (11–15%) women, Paget’s disease
Hypocalcemia (32%) Hypotension (15–32%) [2]
Hypokalemia (29%) Class: Bisphosphonate
Tachycardia (10%) Half-life: >10 years
Hyponatremia (20%)
Hypophosphatemia (21%) Central Nervous System Clinically important, potentially hazardous
Serum creatinine increased (28%) Anorexia (20%) interactions with: none known
Weight gain (11%) Anxiety (8%) Pregnancy category: C
Chills (53%) Important contra-indications noted in the
Hematologic Depression (7%) prescribing guidelines for: nursing mothers;
Anemia (56%) [2] Dysesthesia (15%) pediatric patients
Lymphopenia (22%) Fever (69–85%) [6]
Neutropenia [5] Guillain–Barré syndrome [2] Skin
Ocular Headache (13–24%) [3] Angioedema [2]
Visual disturbances (10%) Insomnia (10%) Erythema multiforme [2]
Other Intracranial hemorrhage [2] Hypersensitivity [3]
Adverse effects [2] Leukoencephalopathy [5] Rash [5]
Rigors (87%)
Tremor (3%) Mucosal
Vertigo (dizziness) (12%) Oral ulceration [9]
ALEFACEPT Neuromuscular/Skeletal Central Nervous System
Asthenia (fatigue) (22–34%) Headache [2]
See: www.drugeruptiondata.com/drug/id/939
Bone or joint pain (24%) Neuromuscular/Skeletal
Myalgia/Myopathy (11%) Arthralgia [6]
Gastrointestinal/Hepatic Bone or joint pain (<6%) [5]
Abdominal pain (11%) Fractures [20]
Diarrhea (10–22%) [2] Osteonecrosis [12]
Nausea (47–54%) [4] Gastrointestinal/Hepatic
Vomiting (33–41%) [2] Abdominal pain (<7%) [8]
Respiratory Dyspepsia [8]
Dyspnea (14–26%) Dysphagia [4]
Flu-like syndrome [2] Esophageal perforation [2]
Pharyngitis (12%) Esophagitis [12]
ALENDRONATE See all our books at www.crcpress.com
Hepatotoxicity [7] Gastrointestinal/Hepatic Nausea [2]

Nausea [7] Abdominal pain (<2%) Respiratory
Vomiting [4] Hepatotoxicity [2] Bronchitis (4%)
Endocrine/Metabolic Respiratory Cough (3%)
Hypocalcemia (18%) [5] Bronchitis (<2%) Influenza (6%) [4]
Renal Pharyngitis (<2%) Nasopharyngitis (11%) [8]
Nephrotoxicity [2] Sinusitis (<2%) Sinusitis (3%) [2]
Renal failure [2] Upper respiratory tract infection (3%) Upper respiratory tract infection [7]
Ocular Genitourinary Endocrine/Metabolic
Conjunctivitis [2] Ejaculatory dysfunction [3] ALT increased [3]
Ocular adverse effects [2] Erectile dysfunction [2] Creatine phosphokinase increased [3]
Ocular inflammation [2] Ocular Genitourinary
Scleritis [3] Floppy iris syndrome [4] Urinary tract infection (5%)
Uveitis [6] Other Ocular
Other Adverse effects [2] Ocular adverse effects [2]
Adverse effects [5] Local
Injection-site pain [2]
ALGLUCERASE Injection-site reactions (7%) [16]
ALFENTANIL Other
See: www.drugeruptiondata.com/drug/id/1054 Adverse effects [4]
See: www.drugeruptiondata.com/drug/id/15 Allergic reactions (9%)
Death [2]
ALGLUCOSIDASE ALFA
ALFUZOSIN
Trade names: Uroxatral (Concordia), Xatral
See: www.drugeruptiondata.com/drug/id/1164 ALISKIREN
(Sanofi-Aventis) See: www.drugeruptiondata.com/drug/id/1225
Indications: Benign prostatic hyperplasia
Class: Adrenergic alpha-receptor antagonist
ALIROCUMAB
Half-life: 10 hours
Trade name: Praluent (Regeneron)
Indications: Adjunct to diet and statin therapy in
ALITRETINOIN
interactions with: ACE inhibitors, adrenergic hypercholesterolemia or clinical atherosclerotic
neurone blockers, alcohol, aldesleukin, Trade name: Panretin (Ligand)
cardiovascular disease where additional lowering Indications: Kaposi’s sarcoma cutaneous lesions
alprostadil, amitriptyline, angiotensin II receptor of low density lipoprotein cholesterol is required
antagonists, antipsychotics, anxiolytics and Class: Retinoid
Class: Monoclonal antibody, Proprotein Half-life: N/A
hypnotics, arsenic, atazanavir, atenolol, baclofen, convertase subtilisin kexin type 9 (PCSK9)
beta blockers, boceprevir, calcium channel Clinically important, potentially hazardous
inhibitor interactions with: ketoconazole, simvastatin,
blockers, cimetidine, citalopram, clonidine, Half-life: 17–20 days
conivaptan, corticosteroids, CYP3A4 inhibitors or vitamin A
Clinically important, potentially hazardous Pregnancy category: D
inducers, darunavir, dasabuvir/ombitasvir/ interactions with: none known
paritaprevir/ritonavir, dasatinib, deferasirox, Important contra-indications noted in the
Pregnancy category: N/A (No data available but prescribing guidelines for: the elderly; pediatric
degarelix, delavirdine, diazoxide, diltiazem, likely to cross the placenta in second and third
diuretics, estrogens, food, general anesthetics, patients
trimester) Note: Oral alitretinoin (Toctino) is not available in
hydralazine, indinavir, itraconazole, ketoconazole, Important contra-indications noted in the
lapatinib, levodopa, levofloxacin, lopinavir, MAO the USA.
prescribing guidelines for: pediatric patients
inhibitors, methyldopa, minoxidil, moxifloxacin,
moxisylyte, moxonidine, nelfinavir, nitrates, Skin
nitroprusside, NSAIDs, pazopanib, Skin Edema (38%)
phosphodiesterase 5 inhibitors, protease Hematoma (2%) Erythema [2]
inhibitors, QT prolonging agents, ritonavir, Cardiovascular Exfoliative dermatitis (39%)
sildenafil, St John’s wort, tadalafil, telaprevir, Cardiotoxicity [3] Pigmentation (3%)
telavancin, telithromycin, tipranavir, tizanidine, Myocardial infarction [3] Pruritus (811%)
vardenafil, voriconazole, vorinostat, ziprasidone Rash (2577%)
Pregnancy category: B Ulcerations (2%)
Cognitive impairment [2]
Important contra-indications noted in the Xerosis (10%)
Headache [4]
prescribing guidelines for: pediatric patients Hair
Neurotoxicity [4]
Stroke [2] Curly hair [2]
Cardiovascular Vertigo (dizziness) [6] Mucosal
Hypotension [2] Neuromuscular/Skeletal Mucocutaneous reactions [2]
Orthostatic hypotension [3]
Arthralgia [6] Cardiovascular
QT prolongation [2]
Asthenia (fatigue) [2] Flushing [2]
Central Nervous System Back pain [5]
Headache (3%) Bone or joint pain (2%) [2] Central Nervous System
Pain (<2%) Muscle spasm (3%) Depression [2]
Vertigo (dizziness) (6%) [19] Myalgia/Myopathy (4%) [7] Headache [7]
Paresthesias (322%)
Neuromuscular/Skeletal Gastrointestinal/Hepatic
Asthenia (fatigue) (3%) Diarrhea (5%) [3] Gastrointestinal/Hepatic
Hepatotoxicity (3%) Nausea [2]
Litt’s Drug Eruption & Reaction Manual ALPRAZOLAM
Endocrine/Metabolic Gastrointestinal/Hepatic
Creatine phosphokinase increased [2] Diarrhea [5] ALOGLIPTIN
Hypertriglyceridemia [2] Hepatotoxicity [7]
Nausea [3] Trade name: Nesina (Takeda)
Indications: Type II diabetes mellitus
Respiratory Class: Antidiabetic, Dipeptidyl peptidase-4 (DPP-
ALLOPURINOL Nasopharyngitis [2] 4) inhibitor
Upper respiratory tract infection [4] Half-life: 21 hours
Trade names: Duzallo (AstraZeneca), Zyloprim Endocrine/Metabolic Clinically important, potentially hazardous
(Prometheus) ALT increased [2] interactions with: none known
Indications: Gouty arthritis AST increased [3] Pregnancy category: B
Class: Purine analog, Xanthine oxidase inhibitor Important contra-indications noted in the
Half-life: <3 hours Renal
Nephrotoxicity [3] prescribing guidelines for: nursing mothers;
Clinically important, potentially hazardous pediatric patients
interactions with: acenocoumarol, amoxicillin, Other
ampicillin, ampicillin/sulbactam, azathioprine, Adverse effects [13]
benazepril, capecitabine, captopril, cilazapril, Allergic reactions (severe) [2] Skin
cyclopenthiazide, dicumarol, enalapril, fosinopril, Death [9] Hypersensitivity [2]
imidapril, lisinopril, mercaptopurine, Pruritus [2]
pantoprazole, quinapril, ramipril, trandolapril, Central Nervous System
uracil/tegafur, vidarabine, zofenopril Headache (4%) [8]
Pregnancy category: C
ALMOTRIPTAN Vertigo (dizziness) [3]
Note: HLA-B*5801 confers a risk of allopurinol- Trade names: Almogran (Almirall), Axert Neuromuscular/Skeletal
induced serious skin reactions like SJS/TEN and (Ortho-McNeil) Arthralgia [2]
DRESS. Indications: Migraine headaches
Duzallo is allopurinol and lesinurad (see separate Gastrointestinal/Hepatic
Class: 5-HT1 agonist, Serotonin receptor agonist, Constipation [2]
entry). Triptan Diarrhea [2]
Half-life: 34 hours Pancreatitis [3]
Skin Clinically important, potentially hazardous
AGEP [6] interactions with: conivaptan, darunavir, Respiratory
DRESS syndrome [45] delavirdine, dihydroergotamine, ergotamine, Nasopharyngitis (4%) [8]
Eosinophilic pustular folliculitis [2] indinavir, ketoconazole, methysergide, SNRIs, Upper respiratory tract infection (4%) [6]
Erythema multiforme [7] SSRIs, telithromycin, triptans, voriconazole Endocrine/Metabolic
Exanthems (<5%) [20] Pregnancy category: C Hypoglycemia [14]
Exfoliative dermatitis (>10%) [15] Important contra-indications noted in the Other
Fixed eruption [11] prescribing guidelines for: pediatric patients Adverse effects [6]
Granuloma annulare (disseminated) [2] Note: Contra-indicated in patients with history, Infection [3]
Hypersensitivity [49] symptoms, or signs of ischemic cardiac,
Lupus erythematosus [3] cerebrovascular, or peripheral vascular
Pityriasis rosea [2] syndromes, or with uncontrolled hypertension.
Pruritus [7] ALOSETRON
Purpura (>10%) [2] Cardiovascular
Rash (>10%) [11] See: www.drugeruptiondata.com/drug/id/18
Chest pain [3]
Stevens-Johnson syndrome (>10%) [53]
Toxic epidermal necrolysis [72] Central Nervous System
Toxic pustuloderma [3] Headache [2] ALPHA-LIPOIC ACID
Toxicity [2] Neurotoxicity [2]
Urticaria (>10%) [6] Paresthesias [4] See: www.drugeruptiondata.com/drug/id/1224
Vasculitis [7] Somnolence (drowsiness) [5]
Vertigo (dizziness) [6]
Hair
Alopecia (<10%) [2] Neuromuscular/Skeletal ALPRAZOLAM
Asthenia (fatigue) [4]
Mucosal
Oral ulceration [3] Gastrointestinal/Hepatic Trade name: Xanax (Pfizer)
Stomatitis [2] Nausea [6] Indications: Anxiety, depression, panic attacks
Vomiting [3] Class: Benzodiazepine
Cardiovascular Half-life: 1116 hours
Polyarteritis nodosa [3] Respiratory
Flu-like syndrome (12%) Clinically important, potentially hazardous
Central Nervous System Upper respiratory tract infection (20%) interactions with: alcohol, amprenavir,
Chills (<10%) aprepitant, boceprevir, clarithromycin, CNS
Fever [2] Other depressants, darunavir, delavirdine, digoxin,
Headache [3] Adverse effects [10] efavirenz, fluconazole, fluoxetine, fluvoxamine,
Vertigo (dizziness) [3] grapefruit juice, indinavir, itraconazole,
Neuromuscular/Skeletal ivermectin, kava, ketoconazole, posaconazole,
Arthralgia [3] propoxyphene, ritonavir, saquinavir, St John’s
Asthenia (fatigue) [2] wort, telaprevir, tipranavir
Back pain [2] Pregnancy category: D
Bone or joint pain [2] Important contra-indications noted in the
Joint disorder [2] prescribing guidelines for: the elderly; nursing
Myalgia/Myopathy [3] mothers; pediatric patients
ALPRAZOLAM Over 100 updates per week on www.drugeruptiondata.com
Skin Central Nervous System

Dermatitis (4%) [5] Fever (>10%) ALVIMOPAN
Diaphoresis (16%) Headache (>10%)
Edema (5%) Pain (>10%) See: www.drugeruptiondata.com/drug/id/1292
Photosensitivity [4] Vertigo (dizziness) (>10%)
Pruritus (<10%) [2] Neuromuscular/Skeletal
Rash (11%) [4] Back pain (<10%) AMANTADINE
Mucosal Gastrointestinal/Hepatic
Sialopenia (33%) See: www.drugeruptiondata.com/drug/id/23
Diarrhea (<10%)
Sialorrhea (4%)
Xerostomia (15%) [6] Respiratory
Cardiovascular
Apnea (>10%)
Cough (<10%)
AMBRISENTAN
Hypotension (<10%) Flu-like syndrome (<10%) Trade names: Letairis (Gilead), Volibris (GSK)
Central Nervous System Sinusitis (<10%) Indications: Pulmonary arterial hypertension
Cognitive impairment (>10%) Genitourinary Class: Antihypertensive, Endothelin receptor
Coma [2] Erectile dysfunction (prolonged erection / (ETR) antagonist, Vasodilator
Depression (>10%) >4 hours) (4%) Half-life: 9 hours
Dysarthria (>10%) Penile pain (>10%) Clinically important, potentially hazardous
Incoordination (<10%) Priapism (4%) [8] interactions with: conivaptan, cyclosporine,
Memory loss [2] Urethral burning (>10%) [2] CYP2C19 inhibitors and inducers, CYP3A4
Neurotoxicity [2] inhibitors and inducers, dasatinib, deferasirox,
Paresthesias (2%) Local
Application-site burning [3] grapefruit juice, St John’s wort
Restlessness [2] Pregnancy category: X
Sedation [2] Application-site erythema [3]
Seizures (<10%) [2] Application-site pain [2]
Somnolence (drowsiness) (>10%) Application-site pruritus [2]
Injection-site ecchymoses (<10%) pediatric patients
Neuromuscular/Skeletal Injection-site hematoma (3%) Note: Also contra-indicated in patients with
Asthenia (fatigue) (>10%) [2] Injection-site pain (2%) idiopathic pulmonary fibrosis.
Endocrine/Metabolic Warning: CONTRA-INDICATED IN
Galactorrhea [2] PREGNANCY
Genitourinary ALTEPLASE Skin

Micturition difficulty (>10%)
Synonym: tPA Edema [3]
Trade name: Activase (Genentech) Peripheral edema (17%) [8]
ALPROSTADIL Indications: Acute myocardial infarction, acute Mucosal

pulmonary embolism Nasal congestion (6%) [2]
Synonyms: PGE; prostaglandin E1 Class: Fibrinolytic, Plasminogen activator Cardiovascular
Trade names: Caverject (Pfizer), Edex Half-life: 3045 minutes Flushing (4%)
(Schwarz), Muse (Vivus), Prostin VR (Pfizer) Clinically important, potentially hazardous Palpitation (5%)
Indications: Impotence, to maintain patent interactions with: defibrotide, nitroglycerin,
ticlopidine Central Nervous System
ductus arteriosus Headache (15%) [3]
Class: Prostaglandin Pregnancy category: C
Half-life: 510 minutes Important contra-indications noted in the Gastrointestinal/Hepatic
Clinically important, potentially hazardous prescribing guidelines for: the elderly; nursing Abdominal pain (3%)
interactions with: acebutolol, alfuzosin, mothers Constipation (4%)
captopril, cilazapril, enalapril, fosinopril, Hepatotoxicity [3]
irbesartan, lisinopril, olmesartan, quinapril, Skin Respiratory
ramipril Anaphylactoid reactions/Anaphylaxis [5] Dyspnea (4%)
Pregnancy category: D (not indicated for use in Angioedema [12] Nasopharyngitis (3%)
women) Ecchymoses (<10%) Sinusitis (3%)
Important contra-indications noted in the Purpura (<10%) Hematologic
prescribing guidelines for: pediatric patients Central Nervous System Anemia [4]
Warning: APNEA (in neonates with congenital Fever (<10%)
heart defects) Intracranial hemorrhage [8]
Skin
Gastrointestinal/Hepatic AMCINONIDE
Hemorrhagic colitis (5%)
Edema (<10%) See: www.drugeruptiondata.com/drug/id/1096
Penile rash (<10%) Hematologic
Bleeding [2]
Mucosal Hemorrhage (4%)
Nasal congestion (<10%)
Other AMIFOSTINE
Cardiovascular Death [4]
Bradycardia (<10%) See: www.drugeruptiondata.com/drug/id/24
Flushing (>10%)
Hypertension (<10%)
Hypotension (<10%) ALTRETAMINE
Tachycardia (<10%)
Litt’s Drug Eruption & Reaction Manual AMINOSALICYLATE SODIUM
Respiratory
AMIKACIN Cough (<10%) AMINOPHYLLINE
Dyspnea (<10%)
Trade name: Amikacin sulfate (Bedford) Synonym: theophylline ethylenediamine
Indications: Short-term treatment of serious Endocrine/Metabolic Trade names: Elixophyllin (Forest), Phyllocontin
infections due to gram-negative bacteria Gynecomastia (<10%) (Napp), Quibron (Monarch)
Class: Antibiotic, aminoglycoside Hyperkalemia [2] Indications: Prevention or treatment of
Half-life: 1.52.5 hours (adults) Genitourinary reversible bronchospasm
Clinically important, potentially hazardous Impotence (<10%) Class: Xanthine alkaloid
interactions with: adefovir, aldesleukin, Half-life: 315 hours (in adult nonsmokers)
aminoglycosides, atracurium, bumetanide, Clinically important, potentially hazardous
cephalexin, doxacurium, ethacrynic acid,
furosemide, succinylcholine, teicoplanin,
AMINOCAPROIC ACID interactions with: adenosine, anagrelide,
arformoterol, azithromycin, BCG vaccine,
torsemide See: www.drugeruptiondata.com/drug/id/27 caffeine, capsicum, carbimazole, cimetidine,
Pregnancy category: D ciprofloxacin, clorazepate, cocoa, erythromycin,
Important contra-indications noted in the eucalyptus, febuxostat, fluvoxamine, halothane,
prescribing guidelines for: nursing mothers; indacaterol, influenza vaccine, levofloxacin,
pediatric patients AMINO- mebendazole, methylprednisolone, moxifloxacin,
Note: Aminoglycosides may cause neurotoxicity nilutamide, norfloxacin, obeticholic acid,
and/or nephrotoxicity.
GLUTETHIMIDE ofloxacin, oral contraceptives, prednisolone,
prednisone, propranolol, rasagiline, raspberry
Skin leaf, roflumilast, ropivacaine, roxithromycin, St
Dermatitis [2] John’s wort, torasemide, torsemide,
Exanthems [2] triamcinolone, zafirlukast
AMINOLEVULINIC Pregnancy category: C
Central Nervous System Important contra-indications noted in the
Neurotoxicity (<10%) ACID prescribing guidelines for: the elderly; nursing
Renal mothers
Trade names: Ameluz (Biofrontera), Levulan
Nephrotoxicity (<10%) [11]
Kerastick (Dusa)
Otic Indications: Non-hyperkeratotic actinic Skin
Hearing loss [5] keratoses of face and scalp Dermatitis [7]
Ototoxicity (<10%) [8] Class: Photosensitizer, Protoporphyrin IX (PpIX) Exanthems [5]
Tinnitus [3] (wakefulness promoting agent) Exfoliative dermatitis [6]
Ocular Half-life: 20–40 hours Hypersensitivity [6]
Macular infarction [3] Clinically important, potentially hazardous Pruritus [3]
interactions with: none known Stevens-Johnson syndrome [3]
Pregnancy category: C Urticaria [6]
Important contra-indications noted in the Cardiovascular
AMILORIDE prescribing guidelines for: nursing mothers; Arrhythmias [2]
pediatric patients Palpitation [3]
Trade names: Midamor (Merck), Moduretic
Note: In photodynamic therapy: to be used in Tachycardia [2]
(Merck)
conjunction with the relevant illuminator as
Indications: Prevention of hypokalemia Central Nervous System
approved by the manufacturer.
associated with kaliuretic diuretics, management Insomnia [2]
of edema in hypertension Seizures [11]
Class: Diuretic, potassium-sparing Skin Tremor [2]
Half-life: 69 hours Burning (>50%) [6] Neuromuscular/Skeletal
Clinically important, potentially hazardous Crusting (6471%) [2] Rhabdomyolysis [5]
interactions with: ACE inhibitors, benazepril, Dermatitis [2]
captopril, cyclosporine, enalapril, fosinopril, Desquamation [2] Gastrointestinal/Hepatic
lisinopril, magnesium, metformin, moexipril, Edema (35%) [9] Abdominal pain [2]
potassium salts, quinapril, quinidine, ramipril, Erosions (14%) [2] Nausea [5]
spironolactone, trandolapril, zofenopril Erythema (99%) [13] Vomiting [2]
Pregnancy category: B Exfoliative dermatitis (from topical Endocrine/Metabolic
Note: Moduretic is amiloride and treatment) [3] SIADH [2]
hydrochlorothiazide. Hydrochlorothiazide is a Hypomelanosis (22%)
Other
sulfonamide and can be absorbed systemically. Photosensitivity [3]
Adverse effects [3]
Sulfonamides can produce severe, possibly fatal, Pigmentation (from topical treatment) (22%)
Allergic reactions [5]
reactions such as toxic epidermal necrolysis and [7]
Death [2]
Stevens-Johnson syndrome. Pruritus (25%) [2]
Pustules (<4%)
Scaling (6471%)
Skin AMINOSALICYLATE
Stinging (>50%) [2]
Photosensitivity [4]
Ulcerations (4%)
Central Nervous System Vesiculation (4%) [2] SODIUM
Headache (<10%)
Central Nervous System See: www.drugeruptiondata.com/drug/id/30
Vertigo (dizziness) (<10%)
Dysesthesia (2%)
Neuromuscular/Skeletal Pain [12]
Asthenia (fatigue) (<10%)
Myalgia/Myopathy (<10%)
AMIODARONE See all our books at www.crcpress.com
Hair Other
AMIODARONE Alopecia [5] Adverse effects [5]
Mucosal Death [8]
Trade names: Cordarone (Wyeth), Pacerone Side effects (12%) [4]
(Upsher-Smith) Sialorrhea (<10%)
Indications: Ventricular fibrillation, ventricular Cardiovascular
tachycardia Arrhythmias (<3%) [3]
Class: Antiarrhythmic, Antiarrhythmic class III, Atrial fibrillation (paroxysmal) [3] AMISULPRIDE
CYP1A2 inhibitor, CYP3A4 inhibitor Atrioventricular block [3]
Half-life: 26107 days Bradycardia [18] See: www.drugeruptiondata.com/drug/id/1281
Clinically important, potentially hazardous Cardiotoxicity [3]
interactions with: abarelix, acebutolol, Flushing (<10%)
acenocoumarol, afatinib, amisulpride, Hypotension (16%) [4] AMITRIPTYLINE
amitriptyline, amprenavir, anisindione, QT prolongation [24]
anticoagulants, arsenic, artemether/lumefantrine, Tachycardia [2] Trade names: Elavil (AstraZeneca), Limbitrol
asenapine, astemizole, atazanavir, atorvastatin, Thrombophlebitis [2] (Valeant)
azoles, betrixaban, boceprevir, bosentan, Torsades de pointes [35] Indications: Depression
carbimazole, celiprolol, cholestyramine, Ventricular arrhythmia [2] Class: Antidepressant, tricyclic, Muscarinic
cimetidine, ciprofloxacin, clopidogrel, cobicistat/ Central Nervous System antagonist
elvitegravir/emtricitabine/tenofovir alafenamide, Anorexia (10–33%) Half-life: 1025 hours
cobicistat/elvitegravir/emtricitabine/tenofovir Coma [2] Clinically important, potentially hazardous
disoproxil, colchicine, cyclosporine, dabigatran, Dysgeusia (taste perversion) (<10%) interactions with: adrenergic neurone blockers,
daclatasvir, darunavir, degarelix, delavirdine, Headache (3–40%) alcohol, alfuzosin, altretamine, amiodarone,
dextromethorphan, dicumarol, digoxin, diltiazem, Insomnia (3–40%) amphetamines, amprenavir, anticholinergics,
disopyramide, dronedarone, droperidol, Neurotoxicity [5] antiepileptics, antihistamines, antimuscarinics,
echinacea, enoxacin, fentanyl, flecainide, Paresthesias (49%) antipsychotics, apraclonidine, arsenic,
fosamprenavir, gatifloxacin, grapefruit juice, Parkinsonism [4] artemether/lumefantrine, aspirin, atomoxetine,
indinavir, ledipasvir & sofosbuvir, lesinurad, Parosmia (<10%) baclofen, barbiturates, brimonidine, bupropion,
levofloxacin, levomepromazine, lidocaine, Peripheral neuropathy [4] cannabis extract, carbamazepine, cimetidine,
lomefloxacin, lopinavir, loratadine, macrolide Syncope [2] cinacalcet, ciprofloxacin, cisapride, clonidine,
antibiotics, methotrexate, moxifloxacin, Tremor (3–40%) [4] clozapine, cobicistat/elvitegravir/emtricitabine/
naldemedine, nelfinavir, nevirapine, nilotinib, Vertigo (dizziness) (3–40%) tenofovir alafenamide, cobicistat/elvitegravir/
norfloxacin, ofloxacin, orlistat, oxprenolol, emtricitabine/tenofovir disoproxil, conivaptan,
pentamidine, phenytoin, pimavanserin, Neuromuscular/Skeletal coumarins, CYP2D6 inhibitors, desmopressin,
procainamide, propranolol, quinidine, quinine, Ataxia [4] dexmethylphenidate, diltiazem, disopyramide,
quinolones, ribociclib, rifabutin, rifampin, Myoclonus [2] disulfiram, diuretics, dronedarone, droperidol,
rifapentine, ritonavir, ropivacaine, rosuvastatin, Rhabdomyolysis [7] duloxetine, entacapone, ephedra, epinephrine,
simvastatin, sofosbuvir & velpatasvir, sofosbuvir/ Gastrointestinal/Hepatic estrogens, eucalyptus, flecainide, gadobutrol,
velpatasvir/voxilaprevir, sotalol, sparfloxacin, St Abdominal pain (<10%) general anesthetics, gotu kola, grapefruit juice,
John’s wort, sulpiride, tacrolimus, telaprevir, Constipation (10–33%) guanethidine, histamine, interferon alfa,
tetrabenazine, thalidomide, tipranavir, trazodone, Hepatic failure [2] iobenguane, isocarboxazid, isoproterenol, kava,
vandetanib, venetoclax, verapamil, warfarin, Hepatic steatosis [2] linezolid, lithium, MAO inhibitors,
zuclopenthixol Hepatitis (<3%) [3] methylphenidate, metoclopramide,
Pregnancy category: D Hepatotoxicity [27] moclobemide, moxifloxacin, moxonidine,
Important contra-indications noted in the Nausea (10–33%) nefopam, nicorandil, nilotinib, nitrates, NSAIDs,
prescribing guidelines for: the elderly; nursing Pancreatitis [4] opioid analgesics, paroxetine hydrochloride,
mothers; pediatric patients Vomiting (10–33%) pentamidine, phenelzine, phenothiazines,
Warning: PULMONARY TOXICITY phenytoin, pimozide, pramlintide, primidone,
Respiratory
propafenone, propoxyphene, protease inhibitors,
Cough [2]
Skin QT interval prolonging agents, quinidine, quinine,
Eosinophilic pneumonia [2]
Anaphylactoid reactions/Anaphylaxis [2] quinolones, rasagiline, ritonavir, saquinavir,
Pneumonia [4]
Angioedema [2] selegiline, sibutramine, sodium oxybate, sotalol,
Pneumonitis [5]
Diaphoresis [2] sparfloxacin, SSRIs, St John’s wort, sulfonylureas,
Pulmonary toxicity [24]
Edema (<10%) terbinafine, tetrabenazine, thioridazine, thyroid
Endocrine/Metabolic hormones, tramadol, tranylcypromine, valerian,
Erythema nodosum [2] Hyperthyroidism (<3%) [10]
Exanthems [5] valproic acid, verapamil, vitamin K antagonists,
Hyponatremia [2] yohimbine, ziprasidone
Facial erythema (3%) [2] Hypothyroidism (<3%) [18]
Iododerma [2] Pregnancy category: C
SIADH [10] Important contra-indications noted in the
Linear IgA bullous dermatosis [6] Thyroid dysfunction [25]
Lupus erythematosus [5] prescribing guidelines for: the elderly; nursing
Thyrotoxicosis [19] mothers; pediatric patients
Myxedema [3]
Photosensitivity (10–75%) [41] Genitourinary Note: Limbitrol is amitriptyline and
Phototoxicity [3] Epididymitis [2] chlordiazepoxide.
Pigmentation (blue) (<10%) [68] Warning: SUICIDALITY AND
Ocular
Pruritus (<5%) [2] ANTIDEPRESSANT DRUGS
Corneal deposits (>90%) [2]
Psoriasis [2] Keratopathy [6]
Purpura (2%) Ocular adverse effects [4] Skin
Toxic epidermal necrolysis [2] Ocular toxicity [2] Diaphoresis (<10%)
Toxicity [5] Optic neuropathy [7] DRESS syndrome [2]
Vasculitis [6] Visual disturbances (2–9%) Photosensitivity [3]
Pigmentation [4]
Litt’s Drug Eruption & Reaction Manual AMOXAPINE
Pruritus [3] Pregnancy category: C Pregnancy category: N/A

Pseudolymphoma [2] Important contra-indications noted in the Important contra-indications noted in the
Purpura [2] prescribing guidelines for: the elderly; nursing prescribing guidelines for: pediatric patients
Mucosal mothers; pediatric patients
Xerostomia (>10%) [16] Note: Caduet is amlodipine and atorvastatin; Skin
Exforge is amlodipine and valsartan; Lotrel is Pruritus [3]
Cardiovascular amlodipine and benazepril; Prestalia is amlodipine
Brugada syndrome [4] and perindopril; Tekamlo is amlodipine and Central Nervous System
Myocardial infarction [2] aliskiren. Extrapyramidal symptoms [3]
Postural hypotension [2] Neuromuscular/Skeletal
QT prolongation [2] Asthenia (fatigue) [4]
Skin
Central Nervous System Angioedema [6] Gastrointestinal/Hepatic
Delirium [2] Dermatitis (<10%) Abdominal pain [3]
Depression [2] Edema (514%) [20] Diarrhea [3]
Dysgeusia (taste perversion) (>10%) [2] Erythema multiforme [2] Vomiting [7]
Hallucinations [3] Exanthems (24%) [2]
Headache [2] Hematologic
Peripheral edema (>10%) [44] Neutropenia [2]
Restless legs syndrome [2] Pigmentation [2]
Sedation [3] Pruritus (24%) [3] Other
Seizures [7] Rash (<10%) Adverse effects [2]
Serotonin syndrome [4] Telangiectasia (facial) [5] Death [2]
Somnolence (drowsiness) [6] Toxic epidermal necrolysis [2]
Vertigo (dizziness) [6] Toxicity [2]
Neuromuscular/Skeletal Vasculitis [2] AMOXAPINE
Asthenia (fatigue) [3] Mucosal
Rhabdomyolysis [2] Gingival hyperplasia/hypertrophy [29] Trade name: Amoxapine (Watson)
Gastrointestinal/Hepatic Indications: Depression
Cardiovascular Class: Antidepressant, tricyclic, Muscarinic
Cholestasis [2] Flushing (<10%) [5]
Constipation [4] antagonist
Hypotension [7] Half-life: 1130 hours
Nausea [2]
Central Nervous System Clinically important, potentially hazardous
Endocrine/Metabolic Headache [12] interactions with: amprenavir, artemether/
SIADH [5] Parkinsonism [2] lumefantrine, clonidine, dronedarone,
Weight gain [7] Syncope [2] epinephrine, fluoxetine, guanethidine,
Otic Vertigo (dizziness) [13] iobenguane, isocarboxazid, linezolid, MAO
Tinnitus [3] Neuromuscular/Skeletal inhibitors, nilotinib, phenelzine, pimozide,
Ocular Asthenia (fatigue) [5] quetiapine, quinine, quinolones, sparfloxacin,
Hallucinations, visual [2] Rhabdomyolysis [2] tetrabenazine, thioridazine, toremifene,
Vision blurred [2] tranylcypromine, vandetanib, vemurafenib,
Gastrointestinal/Hepatic ziprasidone
Other Diarrhea [3] Pregnancy category: C
Adverse effects [5] Gastritis [2] Important contra-indications noted in the
Death [3] Hepatotoxicity [3] prescribing guidelines for: the elderly; nursing
Nausea [5] mothers; pediatric patients
Vomiting [2] Warning: SUICIDALITY AND
AMLEXANOX Respiratory ANTIDEPRESSANT DRUGS
Bronchitis [2]
See: www.drugeruptiondata.com/drug/id/1200 Cough [2] Skin
Upper respiratory tract infection [4] AGEP [3]
Other Diaphoresis (<10%)
AMLODIPINE Adverse effects [8] Edema (<10%)
Exanthems [2]
Trade names: Caduet (Pfizer), Exforge Rash (<10%)
(Novartis), Istin (Pfizer), Lotrel (Novartis), AMOBARBITAL Toxic epidermal necrolysis [2]
Norvasc (Pfizer), Prestalia (Symplmed), Tekamlo Mucosal
(Novartis) See: www.drugeruptiondata.com/drug/id/34 Xerostomia (14%)
Indications: Hypertension, angina
Class: Antiarrhythmic class IV, Calcium channel Central Nervous System
blocker Dysgeusia (taste perversion) (>10%)
Half-life: 3050 hours AMODIAQUINE Headache (<10%)
Clinically important, potentially hazardous Insomnia (<10%)
interactions with: amprenavir, carbamazepine, Trade names: Camoquin (Pfizer), Flavoquin Neuroleptic malignant syndrome [2]
cobicistat/elvitegravir/emtricitabine/tenofovir (Sanofi-Aventis) Somnolence (drowsiness) (14%)
alafenamide, cobicistat/elvitegravir/emtricitabine/ Indications: Malaria Vertigo (dizziness) (<10%)
tenofovir disoproxil, conivaptan, delavirdine, Class: Anti-inflammatory, Antimalarial Neuromuscular/Skeletal
epirubicin, imatinib, phenytoin, primidone, Half-life: 15.7–19.5 hours Asthenia (fatigue) (<10%)
sildenafil, simvastatin, St John’s wort, tadalafil, Clinically important, potentially hazardous
interactions with: none known Gastrointestinal/Hepatic
telaprevir Constipation (12%)
Nausea (<10%)
AMOXAPINE Over 100 updates per week on www.drugeruptiondata.com
Endocrine/Metabolic Hepatotoxicity [36] Neuromuscular/Skeletal

Galactorrhea [2] Nausea [13] Asthenia (fatigue) (13%)
Ocular Vomiting [9] Back pain (12%)
Vision blurred (7%) Genitourinary Gastrointestinal/Hepatic
Other Vaginitis [3] Abdominal pain (20%)
Side effects (5%) Renal Diarrhea (30%)
Nephrotoxicity [2] Gastrointestinal bleeding (10%)
Hepatotoxicity [5]
Other Nausea (40%)
AMOXICILLIN Adverse effects [20] Vomiting (32%)
Kounis syndrome [6]
Synonym: amoxycillin Side effects [4] Respiratory
Trade names: Amoxil (GSK), Augmentin (GSK), Tooth fluorosis [2] Bronchospasm [2]
Prevpac (TAP), Trimox (Bristol-Myers Squibb) Cough (18%)
Indications: Infections of the respiratory tract, Dyspnea (23%)
Hypoxia (8%)
skin and urinary tract
Class: Antibiotic, penicillin
AMPHOTERICIN B Pleural effusion (13%)
Half-life: 0.71.4 hours Pulmonary toxicity (18%)
Trade names: Abelcet (Sigma-Tau), AmBisome Rhinitis (11%)
Clinically important, potentially hazardous (Astellas), Amphocin (Pfizer), Amphotec
interactions with: allopurinol, bromelain, Tachypnea (>10%)
(Alkopharma)
chloramphenicol, demeclocycline, doxycycline, Indications: Potentially life-threatening fungal Endocrine/Metabolic
erythromycin, imipenem/cilastatin, methotrexate, infections ALP increased (22%)
minocycline, omeprazole, oxytetracycline, Class: Antifungal ALT increased (15%)
sulfonamides, tetracycline Half-life: initial: 1548 hours; terminal: 15 days AST increased (13%)
Pregnancy category: B Clinically important, potentially hazardous Creatine phosphokinase increased (22%)
Note: Augmentin is amoxicillin and clavulanic interactions with: adefovir, aminoglycosides, Hyperglycemia (23%)
acid. arsenic, astemizole, betamethasone, cephalothin, Hypernatremia (4%)
cidofovir, cyclosporine, digoxin, ethoxzolamide, Hypervolemia (12%)
Skin fluconazole, flucytosine, ganciclovir, griseofulvin, Hypocalcemia (18%)
AGEP [28] hydrocortisone, itraconazole, ketoconazole, Hypokalemia [2]
Anaphylactoid reactions/Anaphylaxis [15] micafungin, pentamidine, probenecid, sulpiride, Hypomagnesemia (20%)
Angioedema (<10%) [5] terbinafine, triamcinolone, voriconazole Genitourinary
Baboon syndrome (SDRIFE) [11] Pregnancy category: B Hematuria (14%)
Bullous pemphigoid [2] Important contra-indications noted in the Urinary retention (<10%)
Dermatitis [4] prescribing guidelines for: nursing mothers
Renal
DRESS syndrome [6] Nephrotoxicity [50]
Edema [2] Skin
Erythema multiforme [18] Hematologic
Anaphylactoid reactions/Anaphylaxis [4] Anemia (>10%) [4]
Exanthems (>5%) [33] Diaphoresis (7%)
Fixed eruption [10] Leukocytosis (<10%)
Exanthems [4] Sepsis (14%)
Hypersensitivity [5] Peripheral edema (15%)
Jarisch–Herxheimer reaction [2] Pruritus (11%) [2] Local
Linear IgA bullous dermatosis [3] Purpura [3] Infusion-related reactions [5]
Pemphigus [4] Rash (25%) Injection-site pain (>10%)
Pruritus [7] Toxicity [2] Injection-site reactions [5]
Pustules [8] Urticaria [2] Other
Rash (<10%) [14] Adverse effects [5]
Serum sickness-like reaction (<10%) [6] Mucosal
Epistaxis (nosebleed) (15%) Death [4]
Stevens-Johnson syndrome [11] Infection (11%)
Toxic epidermal necrolysis [13] Cardiovascular
Toxic pustuloderma [2] Chest pain (12%)
Urticaria (<5%) [16] Flushing (<10%) [2]
Mucosal Hypertension (8%) [4] AMPICILLIN
Stomatitis [2] Hypotension (14%)
Tachycardia (13%) Trade name: Totacillin (GSK)
Central Nervous System Thrombophlebitis (<10%) Indications: Susceptible strains of gram-negative
Anorexia [2] and gram-positive bacterial infections
Dysgeusia (taste perversion) [6] Central Nervous System Class: Antibiotic, penicillin
Hallucinations [3] Anorexia (>10%) Half-life: 11.5 hours
Headache [5] Anxiety (14%) Clinically important, potentially hazardous
Somnolence (drowsiness) [3] Chills (48%) [5] interactions with: allopurinol, anticoagulants,
Vertigo (dizziness) [5] Confusion (11%) chloramphenicol, cyclosporine, demeclocycline,
Delirium (>10%) doxycycline, erythromycin, levodopa,
Neuromuscular/Skeletal Fever (>10%) [5]
Asthenia (fatigue) [3] methotrexate, minocycline, oxytetracycline,
Headache (20%) sulfonamides, tetracycline
Rhabdomyolysis [2] Insomnia (17%) Pregnancy category: B
Gastrointestinal/Hepatic Leukoencephalopathy [4] Important contra-indications noted in the
Abdominal distension [2] Pain (14%) prescribing guidelines for: nursing mothers
Abdominal pain [7] Paresthesias (<10%) Note: Five to 10% of people taking ampicillin
Diarrhea [18] Parkinsonism [2] develop eruptions between the 5th and 14th day
Dyspepsia [2] following initiation of therapy. Also, there is a
Litt’s Drug Eruption & Reaction Manual ANDROSTENEDIONE
95% incidence of exanthematous eruptions in Pregnancy category: N/A (Contra-indicated in

patients who are treated for infectious AMPRENAVIR women of premenopausal endocrine status,
mononucleosis with ampicillin. The allergenicity including pregnant women)
of ampicillin appears to be enhanced by See: www.drugeruptiondata.com/drug/id/39 Important contra-indications noted in the
allopurinol or by hyperuricemia. Ampicillin is prescribing guidelines for: nursing mothers
clearly the more allergenic of the two drugs when Note: The efficacy of anastrozole in the
given alone. AMYL NITRITE treatment of pubertal gynecomastia in adolescent
boys and in the treatment of precocious puberty
Skin See: www.drugeruptiondata.com/drug/id/40 in girls with McCune-Albright syndrome has not
AGEP [9] been demonstrated.
Anaphylactoid reactions/Anaphylaxis [10]
Angioedema [2] ANAGRELIDE Skin
Baboon syndrome (SDRIFE) [3] Hot flashes (12–36%) [12]
Dermatitis [8] See: www.drugeruptiondata.com/drug/id/896 Lupus erythematosus [3]
Erythema multiforme [11] Peripheral edema (10%)
Exanthems (>10%) [84] Pruritus (25%)
Exfoliative dermatitis [3] ANAKINRA Rash (6–11%) [2]
Fixed eruption [10] Hair
Hypersensitivity [5] Trade name: Kineret (Amgen) Alopecia (25%)
Linear IgA bullous dermatosis [4] Indications: Rheumatoid arthritis, neonatal-
Pemphigus [6] Cardiovascular
onset multisystem inflammatory disease Angina (2%)
Pruritus (<5%) [5] Class: Disease-modulating antirheumatoid drug,
Psoriasis [5] Flushing (>5%)
Interleukin-1 receptor antagonist (IL-IRa) Hypertension (2–13%)
Purpura [6] Half-life: 46 hours
Pustules [4] Thrombophlebitis (25%)
Rash (<10%) interactions with: abatacept, adalimumab, Central Nervous System
Stevens-Johnson syndrome [10] certolizumab, etanercept, golimumab, infliximab, Carpal tunnel syndrome [2]
Toxic epidermal necrolysis [15] lenalidomide, live vaccines Depression (5–13%)
Urticaria [16] Pregnancy category: B Headache (9–13%) [2]
Vasculitis [4] Important contra-indications noted in the Pain (14%)
Hematologic prescribing guidelines for: nursing mothers Tumor pain (>5%)
Thrombocytopenia [2] Neuromuscular/Skeletal
Local Central Nervous System Arthralgia (25%) [8]
Injection-site pain (>10%) Fever (12%) Asthenia (fatigue) (19%) [7]
Headache (12–14%) [2] Back pain (12%) [2]
Other Bone or joint pain (6–11%) [2]
Allergic reactions (<10%) [3] Neuromuscular/Skeletal Joint disorder [3]
Arthralgia (6–12%) Myalgia/Myopathy (25%) [2]
Gastrointestinal/Hepatic Osteoporosis (11%)
AMPICILLIN/ Abdominal pain (5%) Gastrointestinal/Hepatic
Diarrhea (8%) Diarrhea [2]
SULBACTAM Nausea (8%) Hepatitis [2]
Vomiting (14%) Hepatotoxicity [5]
Trade name: Unasyn (Pfizer)
Indications: Various infections caused by Respiratory Nausea (11–19%)
susceptible organisms Flu-like syndrome (6%) Vomiting (8–13%)
Class: Antibiotic, beta-lactam, Antibiotic, Nasopharyngitis (12%) Respiratory
penicillin Sinusitis (7%) Cough (11%)
Half-life: 1 hour Upper respiratory tract infection (4%) [2] Flu-like syndrome (7%)
Clinically important, potentially hazardous Local Pharyngitis (6–14%)
interactions with: allopurinol, probenecid Injection-site edema [2] Endocrine/Metabolic
Pregnancy category: B Injection-site erythema [3] Mastodynia (25%)
Important contra-indications noted in the Injection-site inflammation [2]
prescribing guidelines for: nursing mothers Injection-site pain [4] Genitourinary
Note: Serious and occasionally fatal Injection-site reactions (71%) [31] Vaginal dryness (2%) [2]
hypersensitivity (anaphylactic) reactions have Other Other
been reported in patients on penicillin therapy. Adverse effects [5] Infection (25%)
Contra-indicated in patients with a history of Infection (40%) [11]
hypersensitivity reactions to any of the penicillins.
ANDROSTENEDIONE
Skin ANASTROZOLE
Anaphylactoid reactions/Anaphylaxis [2] See: www.drugeruptiondata.com/drug/id/801
Linear IgA bullous dermatosis [3] Trade name: Arimidex (AstraZeneca)
Rash (<10%) Indications: Breast carcinoma (localized –
Gastrointestinal/Hepatic advanced or metastatic)
Diarrhea (<10%) Class: Antineoplastic, Aromatase inhibitor
Local Half-life: 50 hours
Injection-site pain (16%) Clinically important, potentially hazardous
interactions with: estradiol, estrogens,
tamoxifen
ANIDULAFUNGIN See all our books at www.crcpress.com
Hypoglycemia (7%) Central Nervous System

ANIDULAFUNGIN Hypokalemia (5–15%) Chills [2]
Hypomagnesemia (12%) Fever [3]
Trade names: Ecalta (Pfizer), Eraxis (Pfizer) Guillain–Barré syndrome [2]
Indications: Candidemia, candidal esophagitis Genitourinary
Urinary tract infection (15%) Headache (4–64%) [2]
Class: Antimycobacterial, echinocandin
Half-life: 4050 hours Hematologic Neuromuscular/Skeletal
Clinically important, potentially hazardous Anemia (8–9%) Arthralgia [3]
interactions with: none known Coagulopathy (<2%) Asthenia (fatigue) (5–62%)
Pregnancy category: C Leukocytosis (5%) Myalgia/Myopathy (2–72%) [3]
Important contra-indications noted in the Sepsis (7%) Gastrointestinal/Hepatic
prescribing guidelines for: nursing mothers; Thrombocythemia (6%) Diarrhea (6–8%)
pediatric patients Thrombocytopenia (<2%) Nausea (6%)
Ocular Respiratory
Skin Ocular pain (<2%) Flu-like syndrome [3]
Angioedema (<2%) Vision blurred (<2%) Nasopharyngitis (12–15%)
Erythema (<2%) Visual disturbances (<2%) Genitourinary
Hot flashes (<2%) Local Dysmenorrhea (7%)
Hyperhidrosis (<2%) Infusion-related reactions [2]
Peripheral edema (11%) Local
Pruritus (<2%) Other Injection-site edema [4]
Ulcerations (5%) Adverse effects [3] Injection-site nodules [2]
Urticaria (<2%) Infection (63%) Injection-site pain [4]
Injection-site pruritus [2]
Mucosal Injection-site reactions [6]
Oral candidiasis (5%)
Cardiovascular
ANISINDIONE Other
Allergic reactions [2]
Atrial fibrillation (<2%) See: www.drugeruptiondata.com/drug/id/898
Bundle branch block (<2%)
Chest pain (5%)
Flushing (<2%) [2] ANTI-THYMOCYTE
Hypertension (12%) ANISTREPLASE
Hypotension (15%) GLOBULIN (EQUINE)
Phlebitis [2] See: www.drugeruptiondata.com/drug/id/41
Thrombophlebitis (<2%)
Venous thromboembolism (10%)
Central Nervous System ANTHRAX VACCINE
Confusion (8%)
ANTI-THYMOCYTE
Trade name: BioThrax (Emergent BioSolutions)
Depression (6%)
Fever (9–18%) [3] Indications: Anthrax prophylaxis IMMUNOGLOBULIN
Class: Vaccine
Headache (8%) [5]
Half-life: Requires 1 month to achieve immunity
(RABBIT)
Insomnia (15%)
Rigors (<2%) (92.5% efficient)
Seizures (<2%) Clinically important, potentially hazardous
Vertigo (dizziness) (<2%) interactions with: corticosteroids,
immunosuppressive therapies, other vaccines
Neuromuscular/Skeletal Pregnancy category: D ANTIHEMOPHILIC
Back pain (5%) Important contra-indications noted in the
Gastrointestinal/Hepatic prescribing guidelines for: the elderly; nursing FACTOR
Abdominal pain (6%) mothers; pediatric patients
Synonym: rFV111Fc
Cholestasis (<2%) Note: Dr. Sue Bailey, Assistant Secretary for
Trade names: Afstyla (CSL Behring), Eloctate
Constipation (8%) Health Affairs, released a statement on June 29,
(Biogen Idec), Kovaltry (Bayer)
Diarrhea (9–18%) 1999 that ‘almost one million shots given, the
Indications: Control and prevention of bleeding
Dyspepsia (aggravated) (7%) anthrax immunization is proving to be one of the
episodes in Hemophilia A
Hepatotoxicity [4] safest vaccination programs on record.’ The
Class: Antihemorrhagic, Recombinant fusion
Nausea (7–24%) [4] ADRs reported occurred for ‘50 service
protein
Vomiting (7–18%) [4] members at one installation alone.’ Note that no
Half-life: 20 hours (adults)
Respiratory number of military personnel was mentioned at
this installation, nor did it give any percentages for
Cough (7%) interactions with: none known
the reactions reported.
Dyspnea (12%)
Pleural effusion (10%)
Pneumonia (6%) Skin
Respiratory distress (6%) Diaphoresis [2]
Endocrine/Metabolic Edema (3%) [2]
ALP increased (12%) Hypersensitivity [5]
ALT increased (2%) Lupus erythematosus [2]
Creatine phosphokinase increased (5%) Pruritus (<10%) [2]
Dehydration (6%) Rash [2]
Hyperglycemia (6%) Stevens-Johnson syndrome [2]
Hyperkalemia (6%) Urticaria [2]
Litt’s Drug Eruption & Reaction Manual APREPITANT
Pregnancy category: C Other telithromycin, terfenadine, tolbutamide,

Important contra-indications noted in the Allergic reactions [5] tolvaptan, trabectedin, triamcinolone,
prescribing guidelines for: nursing mothers troleandomycin, vinblastine, vincristine,
voriconazole, warfarin
Pregnancy category: N/A (Insufficient evidence
APREMILAST
APIXABAN to inform drug-associated risk)
Trade name: Otezla (Celgene)
Trade name: Eliquis (Bristol-Myers Squibb) Indications: Psoriatic arthritis, plaque psoriasis prescribing guidelines for: nursing mothers;
Indications: Reduce the risk of stroke and Class: Phosphodiesterase inhibitor, pediatric patients
systemic embolism in patients with nonvalvular Phosphodiesterase type 4 (PDE4) inhibitor Note: Fosaprepitant is a prodrug of aprepitant
atrial fibrillation Half-life: 6–9 hours for injection. Aprepitant treatment is given along
Class: Anticoagulant, Direct factor Xa inhibitor Clinically important, potentially hazardous with a 5-HT3-receptor antagonist and
Half-life: 5–12 hours interactions with: carbamazepine, dexamethasone.
Clinically important, potentially hazardous phenobarbital, phenytoin, rifampin
interactions with: carbamazepine, darunavir, Pregnancy category: C Skin
phenytoin, rifampin, St John’s wort, tipranavir, Important contra-indications noted in the Pruritus (8%)
voriconazole prescribing guidelines for: nursing mothers; Hair
Pregnancy category: B pediatric patients Alopecia (12%)
prescribing guidelines for: nursing mothers; Mucosal
Central Nervous System Mucocutaneous reactions (3%)
pediatric patients Depression [3]
Note: Contra-indicated in patients with active Stomatitis (3%)
Headache (5–6%) [24]
pathological bleeding. Cardiovascular
Warning: DISCONTINUING ELIQUIS IN Neuromuscular/Skeletal Hypertension (2%)
PATIENTS WITHOUT ADEQUATE Arthralgia [2] Hypotension (6%)
CONTINUOUS ANTICOAGULATION Asthenia (fatigue) [5]
INCREASES RISK OF STROKE Gastrointestinal/Hepatic Anorexia (6–10%) [2]
Abdominal pain (<2%) [3] Encephalopathy [2]
Gastrointestinal/Hepatic Diarrhea (8–9%) [28] Fever (3–6%)
Hepatotoxicity [2] Dyspepsia [2] Headache (5–9%) [5]
Nausea (7–9%) [29] Insomnia (2–3%)
Hematologic Vomiting (<3%) [8]
Hemorrhage [15] Somnolence (drowsiness) [2]
Respiratory Vertigo (dizziness) (3–7%) [2]
Other Nasopharyngitis (<3%) [17]
Adverse effects [4] Neuromuscular/Skeletal
Upper respiratory tract infection (<4%) Asthenia (fatigue) (5–18%) [8]
[14]
Gastrointestinal/Hepatic
Endocrine/Metabolic
APOMORPHINE ALT increased [2]
Abdominal pain (5%) [3]
Constipation (9–10%) [8]
Weight loss (10–12%) [5] Diarrhea (<10%) [2]
Other Dyspepsia (5–6%)
Adverse effects [4] Flatulence (4%)
Infection [2] Gastritis (4%)
APRACLONIDINE Nausea (6–13%)
Vomiting (3–8%)
Trade name: Iopidine (Alcon)
Indications: Post-surgical intraocular pressure APREPITANT Endocrine/Metabolic
elevation ALT increased (6%)
Class: Adrenergic alpha2-receptor agonist Trade name: Emend (Merck) AST increased (3%)
Half-life: 8 hours Indications: Prevention of postoperative and Creatine phosphokinase increased (4%)
Clinically important, potentially hazardous chemotherapy induced nausea and vomiting Dehydration (6%)
interactions with: amitriptyline Class: Antiemetic, CYP3A4 inhibitor, Neurokinin Genitourinary
Pregnancy category: C 1 receptor antagonist Urinary tract infection (2%)
Important contra-indications noted in the Half-life: 913 hours
Clinically important, potentially hazardous Renal
interactions with: alprazolam, antifungal agents, Proteinuria (7%)
pediatric patients
astemizole, avanafil, betamethasone, Hematologic
carbamazepine, cisapride, clarithromycin, Anemia (3%)
Skin colchicine, conivaptan, corticosteroids, CYP2C9 Febrile neutropenia [2]
Dermatitis [3] substrates, CYP3A4 inhibitors or inducers, Neutropenia (3–6%) [2]
Pruritus (10%) dasatinib, deferasirox, dexamethasone, diltiazem, Otic
Mucosal docetaxel, eplerenone, estrogens, everolimus, Tinnitus (4%)
Xerostomia (<10%) fentanyl, grapefruit juice, halofantrine, ifosfamide,
imatinib, irinotecan, itraconazole, ketoconazole, Local
Central Nervous System Infusion-site pain [2]
Dysgeusia (taste perversion) (3%) methylprednisolone, midazolam, mifepristone,
naldemedine, nefazodone, neratinib, olaparib, Other
Ocular oral contraceptives, paroxetine hydrochloride, Hiccups (11%) [8]
Conjunctivitis (<5%) phenobarbital, phenytoin, pimecrolimus, Infection [3]
Eyelid edema (<3%) pimozide, progestins, ranolazine, rifampin,
Ocular pruritus (5–15%) rifamycin derivatives, rifapentine, ritonavir,
Xerophthalmia (<5%) salmeterol, saxagliptin, St John’s wort,
APROBARBITAL Over 100 updates per week on www.drugeruptiondata.com
Neuromuscular/Skeletal Central Nervous System

APROBARBITAL Arthralgia (<2%) Agitation (19%) [4]
Back pain (6%) Akathisia (8–13%) [31]
See: www.drugeruptiondata.com/drug/id/44 Leg cramps (4%) Anxiety (17%) [11]
Neck rigidity (<2%) Compulsions [2]
Gastrointestinal/Hepatic Dyskinesia [3]
APROTININ Nausea [2] Extrapyramidal symptoms [9]
Fever (2%)
See: www.drugeruptiondata.com/drug/id/45 Respiratory Headache (27%) [12]
Bronchitis [3] Hypersexuality [2]
COPD (exacerbation) [3] Impulse control disorder [4]
Dysphonia (<2%)
ARBUTAMINE Dyspnea (4%)
Insomnia (18%) [16]
Irritability [4]
Flu-like syndrome (3%) Mania [2]
See: www.drugeruptiondata.com/drug/id/873 Nasopharyngitis [3] Neuroleptic malignant syndrome [14]
Sinusitis (4%) [2] Neurotoxicity [2]
Genitourinary Parkinsonism [11]
ARFORMOTEROL Cystitis (<2%) Psychosis [2]
Nocturia (<2%) Restlessness [8]
Trade name: Brovana (Sunovion) Schizophrenia (exacerbation) [2]
Indications: Chronic obstructive pulmonary Ocular
Glaucoma (<2%) Sedation [10]
disease including chronic bronchitis and Somnolence (drowsiness) (5–11%) [11]
emphysema Visual disturbances (<2%)
Stroke [2]
Class: Beta-2 adrenergic agonist, Bronchodilator Local Suicidal ideation [6]
Half-life: 26 hours Injection-site pain (<2%) Tardive dyskinesia [8]
Clinically important, potentially hazardous Tic disorder [2]
Other
interactions with: aminophylline, beta blockers, Tremor (3%) [9]
Adverse effects [2]
MAO inhibitors, tricyclic antidepressants Vertigo (dizziness) [5]
Allergic reactions (<2%)
Pregnancy category: C
Important contra-indications noted in the Neuromuscular/Skeletal
prescribing guidelines for: nursing mothers; Asthenia (fatigue) [5]
pediatric patients ARGATROBAN Ataxia [4]
Note: Studies in asthma patients showed that Dystonia [13]
long-acting beta2-adrenergic agonists may See: www.drugeruptiondata.com/drug/id/811 Pisa syndrome [2]
increase the risk of asthma-related death. Gastrointestinal/Hepatic
Contra-indicated in patients with asthma without Constipation (11%) [3]
use of a long-term asthma control medication. ARIPIPRAZOLE Dyspepsia (9%)
Warning: ASTHMA-RELATED DEATH Nausea (15%) [10]
Trade names: Abilify (Bristol-Myers Squibb), Vomiting (11%) [5]
Skin Aristada (Alkermes) Respiratory
Abscess (<2%) Indications: Schizophrenia, bipolar I disorder, Cough (3%)
Edema (<2%) major depressive disorder, irritability associated Upper respiratory tract infection [3]
Herpes simplex (<2%) with autistic disorder
Class: Antipsychotic, Mood stabilizer Endocrine/Metabolic
Herpes zoster (<2%) Appetite increased [5]
Neoplasms (<2%) Half-life: 7594 hours
Clinically important, potentially hazardous Diabetes mellitus [2]
Peripheral edema (3%) Galactorrhea [2]
Pigmentation (<2%) interactions with: alcohol, atazanavir,
carbamazepine, CYP3A4 inhibitors, efavirenz, Hyperprolactinemia [2]
Rash (4%) SIADH [2]
Xerosis (<2%) itraconazole, ketoconazole, lopinavir, nelfinavir,
paroxetine hydrochloride, quinidine Weight gain (2–30%) [26]
Mucosal Pregnancy category: C Genitourinary
Oral candidiasis (<2%) Important contra-indications noted in the Priapism [3]
Cardiovascular prescribing guidelines for: the elderly; pediatric Vaginitis [2]
Arteriosclerosis (<2%) patients Hematologic
Atrioventricular block (<2%) Warning: INCREASED MORTALITY IN Neutropenia [2]
Chest pain (7%) [2] ELDERLY PATIENTS WITH DEMENTIA-
Digitalis intoxication (<2%) RELATED PSYCHOSIS Ocular
QT prolongation (<2%) SUICIDALITY AND ANTIDEPRESSANT DRUGS
Vision blurred (3–8%)
Supraventricular tachycardia (<2%) Local
Central Nervous System Injection-site pain [5]
Skin
Agitation (<2%) Rash (6%) [2] Other
Fever (<2%) Adverse effects [4]
Headache [2]
Mucosal
Death [3]
Hypokinesia (<2%) Sialorrhea (4–9%) [5]
Hiccups [3]
Insomnia [2] Xerostomia (5%) [7]
Toothache [2]
Nervousness [3] Cardiovascular
Pain (8%) Arrhythmias [2]
Paresthesias (<2%) Hypertension [3]
Somnolence (drowsiness) (<2%) QT prolongation [2]
Tremor (<2%) [3]
Another random document with
no related content on Scribd:
of tabes dorsalis,
826
of the opium habit,
504
of tubercular meningitis,
723
Home, removal from, question of, in treatment of opium and chloral

habit,
670
671
Home treatment of the insane,
128
,
130
131
133
Homicidal insanity,
146
Hughlings-Jackson on origin of epilepsy,
489
Hydrobromic acid, use, in epilepsy,
501
Hydrocele, spinal,
757
YDROCEPHALUS
,C
HRONIC
740
Definition and synonyms,
740
Diagnosis,
744
Duration,
733
Etiology,
741
Pathological anatomy and prognosis,
744
Spurious, in cerebral anæmia,
785
Symptoms,
741
Treatment,
745
by compression,
745
by evacuation of the fluid by puncture,
745
Medicinal,
745
Hydropathic treatment of hysteria,
282
of neuralgia,
1226
Hydrorachis (see
Spina Bifida
),
757
Hygienic treatment of chronic hydrocephalus,
745
of hemiplegia,
978
of hysteria,
274
of neuralgia,
1223
of tubercular meningitis,
735
Hyoscyamine, use, in painless facial spasm,
462
in torticollis,
464
Hyoscyamus, use, in alcoholism,
645
in brain tumors,
1068
in paralysis agitans,
438
in tremor,
432
in tremors of spinal sclerosis,
905
in tubercular meningitis,
736
Hyperæmia of the brain,

763
Spinal,
801
Hyperæsthesia, hysterical,
250
in acute spinal meningitis,
750
in acute spinal pachymeningitis,
747
in chronic alcoholism,
620
in chronic spinal meningitis,
752
in multiple neuritis,
1195
in symmetrical gangrene,
1259
in tumors of the brain,
1042
of the spinal cord,
1091
1092
Hyperæsthesiæ, varieties of, in nervous diseases,
31-33
Hyperkinesis, in nervous diseases,
44-47
Hypertrophy,
1271
of the brain,
996
Hypnotic catalepsy (hypnotism),
322
373
Hypnotics, use, in cerebral hyperæmia,
773
Hypnotism,
322
373
Hypochondriacal form of general paralysis of the insane,
188
insanity,
150
Hypochondriasis,
154
Hypophosphites, use, in alcoholism,
644
,
646
in general paralysis of the insane,
201
YSTERIA
205
Course, complications, and duration,
258
Definition,
205
Diagnosis,
260
from acute mania,
262
from general nervousness,
262
from hypochondria,
262
from multiple cerebro-spinal sclerosis,
267
from neurotic temperament,
261
from neurasthenia,
262
from spastic spinal paralysis,

267
from spondylitis,
268
from true joint affections,
270
of hysterical blindness and deafness,
271
of hysterical paralyses,
266
Etiology,
216
Age, influence of,
216
Anæmia and chlorosis, influence of,
220
Diatheses, gouty and phthisical, influence of,
214
215
Education, influence of,
218-220
Heredity, influence of,
214
Imitation, influence of,
222-229
Kidneys, movable, influence of,
221
Local and sexual irritation, influence of,
220
221
Menstrual disorders, influence of,
220
Race, climate, and social position, influence of,
217
218
Sex, influence of,
215
History,
207
Pathology,
208-213
Prognosis,
272
Symptoms,
229
Aphonia,
239
Breathing, peculiarities of,
245
Chorea,
242
Clavus hystericus,
252
Contractures,
244
Convulsions and general spasms,
235-237
Dysphagia,
239-245
Ear affections,
249
Erotomania,
235
Eye affections,
247
248
Facies hysterica,
230
Frauds and deceptions,
233
Insanity,
231-233
Joint affections,
251
Local spasms,
244
Locomotor ataxia,
240
Mental state,
230
Nymphomania,
235
Pain,
250
Paralyses, varieties and characters,
237-241
Phantom tumors,
255
Rectal,
240
Sensorial affections,
246-250
Simulating pregnancy,

Textbook Litts Drug Eruption Reaction Manual 24E Jerome Z Litt Ebook All Chapter PDF

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Textbook Litts Drug Eruption Reaction Manual 24E Jerome Z Litt Ebook All Chapter PDF

Uploaded by

Copyright:

Available Formats

Litt's Drug Eruption & Reaction Manual

24E Jerome Z. Litt

Litt's drug eruption & reaction manual Shear

Cooking as a Chemical Reaction: Culinary Science with

Spring Cookbook 1st Edition Jaglale Jerome

Reaction Engineering 1st Edition Shaofen Li

Mathematics for Enzyme Reaction Kinetics and Reactor

Fundamentals of Structural Engineering 2nd Edition

Atmospheric Reaction Chemistry 1st Edition Hajime

Foundations of Chemical Reaction Network Theory Martin

Boca Raton London New York

CRC Press is an imprint of the

© 2018 by Taylor & Francis Group, LLC

No claim to original U.S. Government works

Printed on acid-free paper

International Standard Book Number-13: 978-0-8153-6699-7 (Pack – Paperback and eBook)

Visit the Taylor & Francis Web site at

and the CRC Press Web site at

Litt’s Drug Eruption & Reaction Manual – at a glance

Vigilance at point of care:

Contents of the book, and how to use them

2. Important eruptions / reactions

Local Hematologic Genitourinary

Headache [IV] (10%) [5] Vomiting [2]

Gingivitis (<10%) Other

Chest pain (<5%) Sepsis [2]

Central Nervous System Other Hypokalemia (10%) [3]

Neuromuscular/Skeletal Gastrointestinal perforation [4] Gastrointestinal/Hepatic

busulfan, captopril, carboplatin, carmustine, Depression [3]

Pregnancy category: N/A (Can cause fetal Pneumonia (16%) [3]

Hepatotoxicity [7] Gastrointestinal/Hepatic Nausea [2]

Skin Central Nervous System

Genitourinary ALTEPLASE Skin

ALPROSTADIL Indications: Acute myocardial infarction, acute Mucosal

Pruritus [3] Pregnancy category: C Pregnancy category: N/A

Endocrine/Metabolic Hepatotoxicity [36] Neuromuscular/Skeletal

95% incidence of exanthematous eruptions in Pregnancy category: N/A (Contra-indicated in

Hypoglycemia (7%) Central Nervous System

Pregnancy category: C Other telithromycin, terfenadine, tolbutamide,

Neuromuscular/Skeletal Central Nervous System

of the opium habit,

Home, removal from, question of, in treatment of opium and chloral

Home treatment of the insane,

Hughlings-Jackson on origin of epilepsy,

Hydrobromic acid, use, in epilepsy,

Definition and synonyms,

Pathological anatomy and prognosis,

Spurious, in cerebral anæmia,

by evacuation of the fluid by puncture,

Hydropathic treatment of hysteria,

Hygienic treatment of chronic hydrocephalus,

Hyoscyamine, use, in painless facial spasm,

in tremors of spinal sclerosis,

Hyperæmia of the brain,

in acute spinal meningitis,

in acute spinal pachymeningitis,

in chronic spinal meningitis,

in tumors of the brain,

of the spinal cord,

Hyperæsthesiæ, varieties of, in nervous diseases,

Hypnotic catalepsy (hypnotism),

Hypnotics, use, in cerebral hyperæmia,

Hypochondriacal form of general paralysis of the insane,